

Jan Delaval.

Access DB# 120099

# SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Sabika Aziz Examiner #: 74141 Date: 4/21/04  
Art Unit: 1616 Phone Number: 206 222 2222 Serial Number: 09/619,584  
Mail Box and Bldg Room Location: 4-C70 Room 4445 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or nature of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Bicyclic Arom. Compds  
Inventors (please provide full names): Bernardson, Jean-Michel

Earliest Priority Filing Date: 1/26/1998 (see US 6,147,255)

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search for the compounds  
of class 33

Please see attached sheet

Thank you

## STAFF USE ONLY

	Type of Search	Vendors and cost where applicable
Searcher: <u>Jan</u>	NA Sequence (#) _____	STN <u>✓</u>
Searcher Phone #: <u>C 2204</u>	AA Sequence (#) _____	Dialog _____
Searcher Location: _____	Structure (#) <u>✓</u>	Questel/Orbit _____
Date Searcher Picked Up: <u>4/22</u>	Bibliographic _____	Dr. Link _____
Date Completed: <u>4/22</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Searcher Prep Time: <u>W</u>	Patent Family _____	WWW/Internet _____
Mail Time: <u>175</u>	Other _____	Other (specify) _____

PTC (A 111)

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:58:43 ON 22 APR 2004  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 21 APR 2004 HIGHEST RN 676437-01-7  
 DICTIONARY FILE UPDATES: 21 APR 2004 HIGHEST RN 676437-01-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004


Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more  
 information enter HELP PROP at an arrow prompt in the file or refer  
 to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> d sta que l44

L1 STR



VAR G1=8/9

VAR G2=11/13/15/21/26

VAR G3=ME/32/41

VAR G4=OH/34/36

VAR G5=H/AK/44

NODE ATTRIBUTES:



CONNECT IS M1	RC AT	1
CONNECT IS M1	RC AT	2
CONNECT IS M1	RC AT	4
CONNECT IS M1	RC AT	5
CONNECT IS M1	RC AT	6
CONNECT IS M1	RC AT	44

DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 8  
 GGCAT IS MCY AT 9  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E4 C E1 O AT 8  
 ECOUNT IS E4 C E1 S AT 9

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L3 1038332 SEA FILE=REGISTRY ABB=ON PLU=ON (SC4 OR OC4)/ES AND NR>=2  
 L6 4782 SEA FILE=REGISTRY SUB=L3 SSS FUL L1  
 L7 818 SEA FILE=REGISTRY SUB=L6 CSS FUL L1  
 L9 STR



VAR G1=4/6  
 VAR G2=8/14/21/29/37/40/46/48/17  
 VAR G3=O/S  
 VAR G4=S/H  
 VAR G5=O/H


NODE ATTRIBUTES:

HCOUNT IS M1 AT 10  
 HCOUNT IS M1 AT 11  
 HCOUNT IS M1 AT 18  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 2  
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:  
 RSPEC 8 14 21 29 37 45  
 NUMBER OF NODES IS 52










STEREO ATTRIBUTES: NONE

L11 413 SEA FILE=REGISTRY SUB=L7 SSS FUL L9  
 L12 405 SEA FILE=REGISTRY ABB=ON PLU=ON L7 NOT L11  
 L13 STR



Hy @8

Hy @9



N @44

VAR G1=8/9  
 VAR G2=11/13/15/21/26  
 VAR G3=ME/32/41  
 VAR G4=OH/34/36  
 VAR G5=H/AK/44  
 VAR G6=H/X/AK/OH/34/36

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 1  
 CONNECT IS M1 RC AT 6  
 CONNECT IS M1 RC AT 44

DEFAULT MLEVEL IS ATOM

GGCAT IS MCY AT 8

GGCAT IS MCY AT 9

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS E4 C E1 O AT 8

ECOUNT IS E4 C E1 S AT 9

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE


L15 397 SEA FILE=REGISTRY SUB=L12 CSS FUL L13

L17 STR



VAR G1=8/9  
 VAR G2=11/13/15/21/26  
 VAR G3=ME/32/41  
 VAR G4=OH/34/36  
 VAR G5=H/AK/44  
 VAR G6=H/AK/47/48  
 NODE ATTRIBUTES:  
 CONNECT IS M1 RC AT 2  
 CONNECT IS M1 RC AT 4  
 CONNECT IS M1 RC AT 5  
 CONNECT IS M1 RC AT 44  
 CONNECT IS M1 RC AT 47  
 CONNECT IS M1 RC AT 48  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 8  
 GGCAT IS MCY AT 9  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E4 C E1 O AT 8  
 ECOUNT IS E4 C E1 S AT 9  
 GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE  
 L18      26 SEA FILE=REGISTRY SUB=L15 CSS FUL L17  
 L19      6 SEA FILE=REGISTRY ABB=ON PLU=ON L18 AND (C39H36N2O4 OR  
           C30H37N2O2S OR C28H32NO2PS OR C29H34NO2PS OR C29H34N2O2S OR  
           C30H36N2O2S)  
 L20      STR



VAR G1=8/9  
 VAR G2=11/13/15/21/26  
 VAR G3=ME/32/41  
 VAR G4=OH/34/36  
 VAR G5=H/AK/44  
 REP G6=(1-2) A  
 NODE ATTRIBUTES:  
 CONNECT IS M1 RC AT 2  
 CONNECT IS M1 RC AT 4  
 CONNECT IS M1 RC AT 5  
 CONNECT IS M1 RC AT 44  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 8  
 GGCAT IS MCY AT 9  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E4 C E1 O AT 8  
 ECOUNT IS E4 C E1 S AT 9


GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE

L22 6 SEA FILE=REGISTRY SUB=L15 SSS FUL L20  
 L28 124 SEA FILE=REGISTRY ABB=ON PLU=ON (108-40-7/BI OR 110-91-8/BI  
 OR 1122-91-4/BI OR 119999-22-3/BI OR 1200-07-3/BI OR 123-30-8/B  
 I OR 135631-86-6/BI OR 14804-34-3/BI OR 158115-92-5/BI OR  
 168082-41-5/BI OR 168082-64-2/BI OR 169126-63-0/BI OR 169126-64  
 -1/BI OR 170100-73-9/BI OR 170355-38-1/BI OR 1761-61-1/BI OR  
 18791-75-8/BI OR 189698-90-6/BI OR 189698-91-7/BI OR 189699-37-  
 4/BI OR 191469-48-4/BI OR 196960-59-5/BI OR 196960-60-8/BI OR  
 196960-61-9/BI OR 196960-62-0/BI OR 196960-63-1/BI OR 196960-64  
 -2/BI OR 196960-65-3/BI OR 196960-66-4/BI OR 196960-67-5/BI OR  
 196960-68-6/BI OR 196960-69-7/BI OR 196960-70-0/BI OR 196960-71  
 -1/BI OR 196960-72-2/BI OR 196960-73-3/BI OR 196960-74-4/BI OR  
 196960-75-5/BI OR 196960-76-6/BI OR 196960-77-7/BI OR 196960-78  
 -8/BI OR 196960-79-9/BI OR 196960-80-2/BI OR 196960-81-3/BI OR










196960-82-4/BI OR 196960-83-5/BI OR 196960-84-6/BI OR 196960-85-7/BI OR 196960-86-8/BI OR 196960-87-9/BI OR 196960-88-0/BI OR 196960-89-1/BI OR 196960-90-4/BI OR 196960-91-5/BI OR 196960-92-6/BI OR 196960-93-7/BI OR 196960-94-8/BI OR 196960-95-9/BI OR 196960-96-0/BI OR 196960-97-1/BI OR 196960-98-2/BI OR 196960-99-3/BI OR 196961-00-9/BI OR 196961-01-0/BI OR 196961-02-1/BI OR 196961-03-2/BI OR 196961-04-3/BI OR 196961-05-4/BI OR 196961-06-5/BI OR 196961-07-6/BI OR 196961-08-7/BI OR 196961-09-8/BI OR 196961-10-1/BI OR 196961-11-2/BI OR 196961-12-3/BI OR 196961-13-4/BI OR 196961-14-5/BI OR 196961-15-6/BI OR 196961-16-7/BI OR 196961-17-8/BI OR 196961-18-9/BI OR 196961-19-0/BI OR 196961-20-3/BI OR 196961-21-4/BI OR 196961-22-5/BI OR 196961-23-6/BI OR 196961-24-7/BI OR 196961-25-8/BI OR 196961-26-9/BI OR 196961-27-0/BI OR 196961-28-1/BI OR 196961-29-2/BI OR 196961-30-5/BI OR 196961-31-6/BI OR 196961-32-7/BI OR 196961-33-8/BI OR 196961-34-9/BI OR 196961-35-0/BI OR 196961-36-1/BI OR 196961-37-2/BI OR 19

L29 32 SEA FILE=REGISTRY ABB=ON PLU=ON L28 AND (OC4 OR SC4)/ES  
 L30 28 SEA FILE=REGISTRY ABB=ON PLU=ON L29 AND NR>=2  
 L31 11 SEA FILE=REGISTRY ABB=ON PLU=ON L30 AND (C22H26O2S OR C20H24O3S OR C18H20O3S OR C22H26O2S OR C18H20O3S OR C20H26O3S OR C24H30O2S OR C24H30O2S OR C21H24O2S OR C20H24O3S OR C23H28O2S)  
 L32 STR



Hy @8

Hy @9



N @44

VAR G1=8/9  
 VAR G2=11/13/15/21/26  
 VAR G3=ME/32/41  
 VAR G4=OH/34/36  
 VAR G5=H/AK/44/OH/34

NODE ATTRIBUTES:

CONNECT IS M1 RC AT 1  
 CONNECT IS M1 RC AT 2  
 CONNECT IS M1 RC AT 4  
 CONNECT IS M1 RC AT 5  
 CONNECT IS M1 RC AT 6  
 CONNECT IS M1 RC AT 44  
 DEFAULT MLEVEL IS ATOM  
 GGCAT IS MCY AT 8

GGCAT IS MCY AT 9  
 DEFAULT ECLEVEL IS LIMITED  
 ECOUNT IS E4 C E1 O AT 8  
 ECOUNT IS E4 C E1 S AT 9

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 40

STEREO ATTRIBUTES: NONE

L34 946 SEA FILE=REGISTRY SUB=L3 CSS FUL L32  
 L35 128 SEA FILE=REGISTRY ABB=ON PLU=ON L34 NOT L7  
 L36 62 SEA FILE=REGISTRY SUB=L35 SSS FUL L9  
 L37 11 SEA FILE=REGISTRY ABB=ON PLU=ON L30 AND L35  
 L38 11 SEA FILE=REGISTRY ABB=ON PLU=ON (L31 OR L37)  
 L39 57 SEA FILE=REGISTRY ABB=ON PLU=ON L36 NOT L38  
 L40 12 SEA FILE=REGISTRY ABB=ON PLU=ON L39 AND (C13H9CLO3 OR  
 C13H8CL2O3 OR C13H9BRO3 OR C18H20O3S OR C14H11CLO3 OR C13H8CL2O  
 3 OR C16H13CLO3 OR C18H20O3S)  
 L41 60 SEA FILE=REGISTRY ABB=ON PLU=ON L35 NOT (L38 OR L39 OR L40)  
 L42 5 SEA FILE=REGISTRY ABB=ON PLU=ON L41 AND (C18H16O2S OR  
 C17H18O2S OR C21H24O3 OR C23H28O3 OR C18H20O2S)  
 L43 40 SEA FILE=REGISTRY ABB=ON PLU=ON (L19 OR L22 OR L38 OR L40 OR  
 L42)  
 L44 36 SEA FILE=REGISTRY ABB=ON PLU=ON L43 NOT QUINAZOL?

=> d his

(FILE 'HOME' ENTERED AT 12:50:26 ON 22 APR 2004)  
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 12:50:36 ON 22 APR 2004

L1 STR  
 L2 0 S L1 CSS  
 L3 1038332 S (SC4 OR OC4)/ES AND NR>=2  
 L4 5 S L1 CSS SAM SUB=L3  
 L5 21 S L1 SAM SUB=L3  
 L6 4782 S L1 FUL SUB=L3  
 SAV L6 QAZI619/A TEMP  
 L7 818 S L1 CSS FUL SUB=L6  
 SAV TEMP L7 QAZI619A/A

FILE 'HCAOLD' ENTERED AT 13:00:22 ON 22 APR 2004

L8 5 S L7

FILE 'REGISTRY' ENTERED AT 13:07:05 ON 22 APR 2004

L9 STR  
 L10 16 S L9 SAM SUB=L7  
 L11 413 S L9 FUL SUB=L7  
 SAV L11 QAZI619B/A  
 L12 405 S L7 NOT L11  
 L13 STR L1  
 L14 18 S L13 CSS SAM SUB=L12  
 L15 397 S L13 CSS FUL SUB=L12  
 SAV L15 QAZI619C/A  
 L16 STR L13  
 L17 STR L16  
 L18 26 S L17 CSS FUL SUB=L15  
 SAV L18 QAZI619D/A  
 L19 6 S L18 AND (C39H36N2O4 OR C30H37N2O2S OR C28H32N2O2PS OR C29H34NO  
 L20 STR L17  
 L21 0 S L20 SAM SUB=L15



L22 6 S L20 FUL SUB=L15  
SAV L22 QAZI619E/A

FILE 'HCAOLD' ENTERED AT 13:25:53 ON 22 APR 2004

L23 0 S L19 OR L22

FILE 'HCAPLUS' ENTERED AT 13:25:56 ON 22 APR 2004

L24 5 S L19 OR L22  
E BERNARDON J/AU

L25 68 S E4-E7  
E GALDERM/PA,CS

L26 169 S E3-E38

L27 1 S (FR96-3235 OR WO97-FR391)/AP,PRN OR (US6147255 OR US6515021 O  
SEL RN

FILE 'REGISTRY' ENTERED AT 13:28:27 ON 22 APR 2004

L28 124 S E1-E124

L29 32 S L28 AND (OC4 OR SC4)/ES

L30 28 S L29 AND NR>=2

L31 11 S L30 AND (C22H26O2S OR C20H24O3S OR C18H20O3S OR C22H26O2S OR  
L32 STR L1

L33 6 S L32 CSS SAM SUB=L3

L34 946 S L32 CSS FUL SUB=L3  
DEL QAZI619?/A  
SAV L34 QAZI619A/A

L35 128 S L34 NOT L7

L36 62 S L9 FUL SUB=L35  
SAV L36 QAZI619B/A

L37 11 S L30 AND L35

L38 11 S L31,L37

L39 57 S L36 NOT L38

L40 12 S L39 AND (C13H9CLO3 OR C13H8CL2O3 OR C13H9BRO3 OR C18H20O3S OR

L41 60 S L35 NOT L38-L40

L42 5 S L41 AND (C18H16O2S OR C17H18O2S OR C21H24O3 OR C23H28O3 OR C1

L43 40 S L19,L22,L38,L40,L42

L44 36 S L43 NOT QUINAZOL?  
SAV QAZI619C/A L44

FILE 'HCAOLD' ENTERED AT 13:57:48 ON 22 APR 2004

L45 0 S L44

FILE 'HCAPLUS' ENTERED AT 13:57:52 ON 22 APR 2004

L46 11 S L44

L47 2 S L46 AND L25-L27

L48 9 S L46 NOT L47

FILE 'USPATFULL, USPAT2' ENTERED AT 13:58:20 ON 22 APR 2004


L49 9 S L46

FILE 'REGISTRY' ENTERED AT 13:58:43 ON 22 APR 2004

=> d ide can tot l44

L44 ANSWER 1 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 675579-71-2 REGISTRY  
CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C21 H24 O3  
SR CA  
LC STN Files: CAPLUS

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 2 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 675579-70-1 REGISTRY  
 CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-furanyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C23 H28 O3  
 SR CA  
 LC STN Files: CAPLUS

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L44 ANSWER 3 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
 RN 493037-21-1 REGISTRY  
 CN Benzeneacetamide, N-[2-benzoyl-4-[[ (2E)-3-[5-[4-(1,1-dimethylethyl)phenyl]-2-furanyl]-1-oxo-2-propenyl]amino]phenyl]-4-methyl-, (9CI) (CA INDEX NAME)  
 FS STEREOSEARCH  
 MF C39 H36 N2 O4  
 SR CA  
 LC STN Files: CA, CAPLUS, CASREACT

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:137101

L44 ANSWER 4 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 493037-17-5 REGISTRY  
CN Benzeneacetamide, N-[2-benzoyl-4-[[[(2E)-3-[5-(2-naphthalenyl)-2-furanyl]-1-oxo-2-propenyl]amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C39 H30 N2 O4  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:137101


L44 ANSWER 5 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 463351-44-2 REGISTRY  
CN 2-Propenoic acid, 3-[5-(2,3-dichlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD

MF C13 H8 Cl2 O3  
SR Chemical Library  
LC STN Files: CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L44 ANSWER 6 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 372155-49-2 REGISTRY  
CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]-, 2-propenyl ester  
(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C16 H13 Cl O3  
SR Chemical Library  
LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L44 ANSWER 7 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 329795-33-7 REGISTRY  
CN 2-Propenoic acid, 3-[5-(2,5-dichlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C13 H8 Cl2 O3  
SR Chemical Library  
LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L44 ANSWER 8 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN


RN 301654-93-3 REGISTRY  
CN 2-Propenoic acid, 3-[5-(3-bromophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C13 H9 Br O3  
SR Chemical Library  
LC STN Files: CHEMCATS



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L44 ANSWER 9 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 285565-66-4 REGISTRY  
CN Furan, 2,3-dihydro-2-(2-naphthalenyl)-4-(1E)-1-propenyl- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C17 H16 O  
SR CA  
LC STN Files: CA, CAPLUS

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 133:135199

L44 ANSWER 10 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 241140-33-0 REGISTRY  
CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]- (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C18 H20 O3 S  
SR CA  
LC STN Files: CA, CAPLUS

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:194472

L44 ANSWER 11 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 241140-32-9 REGISTRY  
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C18 H20 O3 S  
SR CA  
LC STN Files: CA, CAPLUS

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:194472

L44 ANSWER 12 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 229008-57-5 REGISTRY  
CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)-  
(9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C17 H18 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 13 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 229008-56-4 REGISTRY  
CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C18 H20 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 14 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 229008-54-2 REGISTRY  
CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C17 H18 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 15 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229006-12-6 REGISTRY

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)


FS STEREOSEARCH

MF C30 H37 N2 O2 S . I

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



● I<sup>-</sup>

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 16 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229006-08-0 REGISTRY

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

FS STEREOSEARCH


MF C30 H36 N2 O2 S

SR CA



LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 17 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN

RN 229006-06-8 REGISTRY

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA  
INDEX NAME)


FS STEREOSEARCH

MF C29 H34 N2 O2 S

SR CA

LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 18 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 229006-02-4 REGISTRY  
CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C29 H34 N O2 P S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.




2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 19 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 229006-01-3 REGISTRY  
CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C28 H32 N O2 P S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL

Double bond geometry as shown.




2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 131:87834

REFERENCE 2: 131:73571

L44 ANSWER 20 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196961-08-7 REGISTRY  
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C23 H28 O2 S

SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 21 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196961-06-5 REGISTRY  
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C24 H30 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 22 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196961-04-3 REGISTRY  
CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C24 H30 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 23 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196961-02-1 REGISTRY  
CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H24 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 24 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196961-00-9 REGISTRY  
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
, ethyl ester (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C20 H24 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 25 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-65-3 REGISTRY  
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C21 H24 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 26 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-64-2 REGISTRY  
CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H26 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 27 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-63-1 REGISTRY  
CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C22 H26 O2 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 28 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-62-0 REGISTRY  
CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H20 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 29 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-61-9 REGISTRY  
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H20 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 30 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 196960-59-5 REGISTRY  
CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C18 H20 O3 S  
SR CA  
LC STN Files: CA, CAPLUS, USPATFULL




**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 127:293119

L44 ANSWER 31 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 129626-52-4 REGISTRY  
CN 2-Propenoic acid, 3-[5-(2-bromophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C13 H9 Br O3  
SR CA  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CHEMCATS  
(\*File contains numerically searchable property data)

Double bond geometry as shown.



**\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\***


1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 113:152173

L44 ANSWER 32 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 62806-36-4 REGISTRY  
CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C13 H9 Cl O3  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CHEMCATS  
(\*File contains numerically searchable property data)

Double bond geometry as shown.






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 86:188948

L44 ANSWER 33 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 58110-51-3 REGISTRY  
CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]-, methyl ester (9CI)  
(CA INDEX NAME)  
FS 3D CONCORD  
MF C14 H11 Cl O3  
LC STN Files: CA, CAPLUS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 84:58390

L44 ANSWER 34 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 58110-41-1 REGISTRY  
CN 2-Propenoic acid, 3-[5-(2-bromophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C13 H9 Br O3  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CASREACT, CHEMCATS  
(\*File contains numerically searchable property data)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 109:110184

REFERENCE 2: 84:58390

L44 ANSWER 35 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 58110-39-7 REGISTRY  
CN 2-Propenoic acid, 3-[5-(2-chlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C13 H9 Cl O3  
LC STN Files: CA, CAPLUS, CHEMCATS




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 84:58390

L44 ANSWER 36 OF 36 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 58110-38-6 REGISTRY  
CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C13 H9 Cl O3  
LC STN Files: BEILSTEIN\*, CA, CAPLUS, CHEMCATS  
(\*File contains numerically searchable property data)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 84:58390

=> fil uspatall

FILE 'USPATFULL' ENTERED AT 13:59:02 ON 22 APR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:59:02 ON 22 APR 2004  
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs hitstr tot 149

L49 ANSWER 1 OF 9 USPATFULL on STN  
AN 2003:195242 USPATFULL  
TI Bicyclic aromatic compounds


IN Bernardon, Jean-Michel, Le Rouret, FRANCE  
 PI US 2003135053 A1 20030717  
 AI US 2003-334978 A1 20030102 (10)  
 RLI Continuation of Ser. No. US 2000-619584, filed on 19 Jul 2000, PENDING  
 Division of Ser. No. US 1998-952804, filed on 26 Jan 1998, GRANTED, Pat.  
 No. US 6147255 A 371 of International Ser. No. WO 1997-FR391, filed on 5  
 Mar 1997, UNKNOWN  
 PRAI FR 1996-3235 19960314  
 DT Utility  
 FS APPLICATION  
 LREP BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box 1404, Alexandria, VA,  
 22313-1404  
 CLMN Number of Claims: 11  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Page(s)  
 LN.CNT 1588  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention relates to novel bicyclic aromatic compounds which have  
 the general formula (I): ##STR1##

as well as to the use of these compounds in pharmaceutical compositions  
 intended for use in human or veterinary medicine (dermatological,  
 rheumatic, respiratory, cardiovascular and ophthalmological complaints  
 in particular), or alternatively in cosmetic compositions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196960-59-5P 196960-61-9P 196960-62-0P  
 196960-63-1P 196960-64-2P 196960-65-3P  
 (preparation of bicyclic aromatic compds.)


RN 196960-59-5 USPATFULL  
 CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
 (9CI) (CA INDEX NAME)



RN 196960-61-9 USPATFULL  
 CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
 (9CI) (CA INDEX NAME)




RN 196960-62-0 USPATFULL  
 CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
 (9CI) (CA INDEX NAME)




RN 196960-63-1 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-64-2 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 196961-00-9P 196961-02-1P 196961-04-3P

196961-06-5P 196961-08-7P

(preparation of bicyclic aromatic compds.)


RN 196961-00-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-02-1 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-04-3 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-06-5 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 2 OF 9 USPATFULL on STN

AN 2003:86883 USPATFULL

TI Bicyclic aromatic compounds

IN Bernardon, Jean-Michel, Le Rouret, FRANCE

PI US 2003060491 A1 20030327

AI US 2002-252514 A1 20020924 (10)

RLI Division of Ser. No. US 2000-619582, filed on 19 Jul 2000, PENDING  
Continuation of Ser. No. US 1998-952804, filed on 26 Jan 1998, GRANTED,  
Pat. No. US 6147255 A 371 of International Ser. No. WO 1997-FR391, filed  
on 5 Mar 1997, UNKNOWN

PRAI FR 1996-3235 19960314

DT Utility

FS APPLICATION

LREP Norman H. Stepno, BURNS, DOANE, SWECKER & MATHIS, L.L.P., P.O. Box1404,  
Alexandria, VA, 22313-1404

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 1 Drawing Page(s)

LN.CNT 1584

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel bicyclic aromatic compounds which have  
the general formula (I): ##STR1##

as well as to the use of these compounds in pharmaceutical compositions  
intended for use in human or veterinary medicine (dermatological,  
rheumatic, respiratory, cardiovascular and ophthalmological complaints  
in particular), or alternatively in cosmetic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 196960-59-5P 196960-61-9P 196960-62-0P

196960-63-1P 196960-64-2P 196960-65-3P

(preparation of bicyclic aromatic compds.)


RN 196960-59-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-61-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-62-0 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-63-1 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-64-2 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 196961-00-9P 196961-02-1P 196961-04-3P

196961-06-5P 196961-08-7P

(preparation of bicyclic aromatic compds.)


RN 196961-00-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-02-1 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-04-3 USPATFULL


CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-06-5 USPATFULL


CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)





RN 196961-08-7 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 3 OF 9 USPATFULL on STN

AN 2003:33507 USPATFULL

TI Bicyclic aromatic compounds

IN Bernardon, Jean-Michel, Le Rouret, FRANCE

PA Centre International de Recherches Dermatologiques Galderma, Valbonne, FRANCE (non-U.S. corporation)

PI US 6515021 B1 20030204

AI US 2000-619582 20000912 (9)

RLI Continuation of Ser. No. US 952804, now patented, Pat. No. US 6147255

PRAI FR 1996-3235 19960314

DT Utility

FS GRANTED

EXNAM Primary Examiner: Qazi, Sabiha

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 9

ECL Exemplary Claim: 1

DRWN 2 Drawing Figure(s); 1 Drawing Page(s)

LN.CNT 1480

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to novel bicyclic aromatic compounds which have the general formula (I): ##STR1##

as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 196960-59-5P 196960-61-9P 196960-62-0P

196960-63-1P 196960-64-2P 196960-65-3P

(preparation of bicyclic aromatic compds.)


RN 196960-59-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-61-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-62-0 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
(9CI) (CA INDEX NAME)




RN 196960-63-1 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-64-2 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 196961-00-9P 196961-02-1P 196961-04-3P

196961-06-5P 196961-08-7P

(preparation of bicyclic aromatic compds.)


RN 196961-00-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-02-1 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-04-3 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-06-5 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 4 OF 9 USPATFULL on STN

AN 2002:160710 USPATFULL

TI Anilide derivative, production and use thereof

IN Shiraishi, Mitsuru, Hyogo, JAPAN

Kitayoshi, Takahito, Osaka, JAPAN

Aramaki, Yoshio, Hyogo, JAPAN

Honda, Susumu, Hyogo, JAPAN

Oda, Tsuneo, Osaka, JAPAN

PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)

PI US 6413947 B1 20020702

AI US 2000-661194 20000913 (9)

RLI Division of Ser. No. US 1998-213379, filed on 17 Dec 1998, now patented, Pat. No. US 6166006

PRAI JP 1997-351481 19971219

DT Utility

FS GRANTED

EXNAM Primary Examiner: Powers, Fiona T.

LREP Wenderoth, Lind & Ponack, L.L.P.

CLMN Number of Claims: 18

ECL Exemplary Claim: 1

DRWN 0 Drawing Figure(s); 0 Drawing Page(s)

LN.CNT 15864

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is to provide a compound of the formula: ##STR1##

wherein R<sup>sup.1</sup> is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: ##STR2##

wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R<sup>sup.2</sup> is (1) an, optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229006-01-3P 229006-02-4P 229006-06-8P  
229006-08-0P 229006-12-6P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)-(9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 USPATFULL

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




● I<sup>-</sup>

IT 229008-54-2P 229008-56-4P 229008-57-5P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)


RN 229008-54-2 USPATFULL  
 CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229008-56-4 USPATFULL  
 CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229008-57-5 USPATFULL  
 CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L49 ANSWER 5 OF 9 USPATFULL on STN  
 AN 2002:88517 USPATFULL  
 TI Quaternary ammonium salts and their use  
 IN Shiraishi, Mitsuru, Hyogo, JAPAN  
 Baba, Masanori, Kagoshima, JAPAN  
 Aramaki, Yoshio, Hyogo, JAPAN  
 Nishimura, Osamu, Ibaraki, JAPAN  
 Kanzaki, Naoyuki, Osaka, JAPAN  
 PA Takeda Chemical Industries, Ltd., Osaka, JAPAN (non-U.S. corporation)  
 PI US 6376536 B1 20020423  
 AI US 2000-580270 20000526 (9)  
 RLI Division of Ser. No. US 1999-377040, filed on 19 Aug 1999, now patented,  
 Pat. No. US 6096780  
 PRAI JP 1998-234388 19980820  
 US 1998-104845P 19981016 (60)  
 DT Utility  
 FS GRANTED

EXNAM Primary Examiner: Solola, T. A.  
 LREP Wenderoth, Lind & Ponack, L.L.P.  
 CLMN Number of Claims: 7  
 ECL Exemplary Claim: 1  
 DRWN 0 Drawing Figure(s); 0 Drawing Page(s)  
 LN.CNT 2156

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is to provide a compound for antagonizing CCR5, said compound being represented by the formula: ##STR1##

wherein R.sup.1 is an optionally substituted phenyl or an optionally substituted thienyl; Y is --CH.sub.2--, --S-- or --O--; and R.sup.2, R.sup.3 and R.sup.4 are independently an optionally substituted aliphatic hydrocarbon group or an optionally substituted alicyclic heterocyclic ring group, and being effective for the prevention and treatment of infectious disease of HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229006-01-3P 229006-02-4P 229006-06-8P  
 229006-08-0P 229006-12-6P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229006-06-8 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.






RN 229006-08-0 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)-(9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 USPATFULL

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-  
methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-,  
iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

● I<sup>-</sup>


IT 229008-54-2P 229008-56-4P 229008-57-5P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides,  
naphthalenecarboxamides, and related compds. as MCP-1 receptor  
antagonists)

RN 229008-54-2 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L49 ANSWER 6 OF 9 USPATFULL on STN

AN 2001:121461 USPATFULL

TI Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative

IN Nishimura, Osamu, Hyogo, Japan  
 Baba, Masanori, Kagoshima, Japan  
 Sawada, Hidekazu, Osaka, Japan  
 Kanzaki, Naoyuki, Osaka, Japan  
 Kuroshima, Ken-ichi, Osaka, Japan  
 Shiraishi, Mitsuru, Hyogo, Japan  
 Aramaki, Yoshio, Hyogo, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

PI US 6268354 B1 20010731

AI US 2000-661320 20000913 (9)

RLI Division of Ser. No. US 1998-213377, filed on 17 Dec 1998, now patented,  
 Pat. No. US 6172061

PRAI JP 1997-351480 19971219

JP 1998-218875 19980803  
 JP 1998-234388 19980820  
 US 1998-104847P 19981116 (60)  
 US 1998-104845P 19981116 (60)  
 DT Utility  
 FS GRANTED  
 EXNAM Primary Examiner: Powers, Fiona T.  
 LREP Wenderoth, Lind & Ponack, L.L.P.  
 CLMN Number of Claims: 21  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 16650

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is to provide a pharmaceutical composition for antagonizing CCR5 which comprises a compound of the formula: ##STR1##

wherein R<sup>sup.1</sup> is an optionally substituted 5- to 6-membered ring; W is a divalent group of the formula: ##STR2##

wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R<sup>sup.2</sup> is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229006-01-3P 229006-02-4P 229006-06-8P  
 229006-08-0P 229006-12-6P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 USPATFULL

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-  
methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-,  
iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I<sup>-</sup>


IT 229008-54-2P 229008-56-4P 229008-57-5P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229008-54-2 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L49 ANSWER 7 OF 9 USPATFULL on STN  
 AN 2000:174633 USPATFULL  
 TI Anilide derivative, production and use thereof  
 IN Shiraishi, Mitsuru, Hyogo, Japan  
 Kitayoshi, Takahito, Osaka, Japan  
 Aramaki, Yoshio, Hyogo, Japan  
 Honda, Susumu, Hyogo, Japan  
 Oda, Tsuneo, Osaka, Japan  
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)  
 PI US 6166006 20001226  
 AI US 1998-213379 19981217 (9)  
 PRAI JP 1997-351481 19971219  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Powers, Fiona T.  
 LREP Wenderoth, Lind & Ponack, L.L.P.  
 CLMN Number of Claims: 26  
 ECL Exemplary Claim: 1  
 DRWN No Drawings  
 LN.CNT 15554

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is to provide a compound of the formula: ##STR1## wherein R.sup.1 is an optionally substituted 5- to 6-membered ring; C is a divalent group of the formula: ##STR2## wherein the ring A is an optionally substituted 5- to 6-membered aromatic ring, X is an optionally substituted C, N or O atom, and the ring B is an optionally substituted 5- to 7-membered ring; Z is a chemical bond or a divalent group; R.sup.2 is (1) an optionally substituted amino group in which a nitrogen atom may form a quaternary ammonium, etc., or a salt thereof, which is useful for antagonizing MCP-1 receptor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 229006-01-3P 229006-02-4P 229006-06-8P  
 229006-08-0P 229006-12-6P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 USPATFULL

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I<sup>-</sup>


IT 229008-54-2P 229008-56-4P 229008-57-5P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229008-54-2 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229008-57-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.





L49 ANSWER 8 OF 9 USPATFULL on STN  
 AN 2000:153887 USPATFULL  
 TI Bicyclic-aromatic compounds  
 IN Bernardon, Jean-Michel, Le Rouret, France  
 PA Centre International de Recherches Dermatologiques Galderma, Valbonne, France (non-U.S. corporation)  
 PI US 6147255 20001114  
 WO 9733881 19970918  
 AI US 1998-952804 19980126 (8)  
 WO 1997-FR391 19970305  
 19980126 PCT 371 date  
 19980126 PCT 102(e) date  
 PRAI FR 1996-3235 19960314  
 DT Utility  
 FS Granted  
 EXNAM Primary Examiner: Oazi, Sabiha  
 LREP Burns, Doane, Swecker & Mathis, L.L.P.  
 CLMN Number of Claims: 10  
 ECL Exemplary Claim: 1  
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)  
 LN.CNT 1471

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to novel bicyclic aromatic compounds which have the general formula (I): ##STR1## as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 196960-59-5P 196960-61-9P 196960-62-0P  
 196960-63-1P 196960-64-2P 196960-65-3P  
 (preparation of bicyclic aromatic compds.)


RN 196960-59-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
 (9CI) (CA INDEX NAME)




RN 196960-61-9 USPATFULL


CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-  
 (9CI) (CA INDEX NAME)




RN 196960-62-0 USPATFULL  
 CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-  
 (9CI) (CA INDEX NAME)




RN 196960-63-1 USPATFULL  
 CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-64-2 USPATFULL  
 CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 USPATFULL  
 CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 196961-00-9P 196961-02-1P 196961-04-3P

196961-06-5P 196961-08-7P

(preparation of bicyclic aromatic compds.)


RN 196961-00-9 USPATFULL

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-02-1 USPATFULL

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-04-3 USPATFULL

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-06-5 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 USPATFULL

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



L49 ANSWER 9 OF 9 USPATFULL on STN

AN 2000:98464 USPATFULL

TI Quaternary ammonium salts and their use

IN Shiraishi, Mitsuru, Hyogo, Japan

Baba, Masanori, Kagoshima, Japan

Aramaki, Yoshio, Hyogo, Japan

Nishimura, Osamu, Ibaraki, Japan

Kanzaki, Naoyuki, Osaka, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)

PI US 6096780 20000801

AI US 1999-377040 19990819 (9)

PRAI JP 1998-234388 19980820

US 1998-104845P 19981016 (60)

DT Utility

FS Granted

EXNAM Primary Examiner: Lambkin, Deborah C.

LREP Wenderoth, Lind & Ponack, LLP.

CLMN Number of Claims: 22

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 2169

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention is to provide a compound for antagonizing CCR5, said compound being represented by the formula: ##STR1## wherein R.sup.1 is an optionally substituted phenyl or an optionally substituted thienyl; Y is --CH.sub.2-- , --S-- or --O--; and R.sup.2, R.sup.3 and R.sup.4 are independently an optionally substituted aliphatic hydrocarbon group or an optionally substituted alicyclic heterocyclic ring group, and being effective for the prevention and treatment of infectious disease of HIV.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 229006-01-3P 229006-02-4P 229006-06-8P


229006-08-0P 229006-12-6P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 USPATFULL

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 USPATFULL

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● I<sup>-</sup>


IT 229008-54-2P 229008-56-4P 229008-57-5P

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229008-54-2 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 USPATFULL

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)-  
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 13:59:23 ON 22 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Apr 2004 VOL 140 ISS 17

FILE LAST UPDATED: 21 Apr 2004 (20040421/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all hitstr tot 148

L48 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 2004:202648 HCAPLUS

ED Entered STN: 14 Mar 2004

TI Structure-Based Design of Potent Retinoid X Receptor  $\alpha$  Agonists

AU Haffner, Curt D.; Lenhard, James M.; Miller, Aaron B.; McDougald, Darryl L.; Dwornik, Kate; Ittoop, Olivia R.; Gampe, Robert T., Jr.; Xu, H. Eric; Blanchard, Steve; Montana, Valerie G.; Consler, Tom G.; Bledsoe, Randy K.; Ayscue, Andrea; Croom, Dallas

CS GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA

SO Journal of Medicinal Chemistry (2004), 47(8), 2010-2029

CODEN: JMCMAR; ISSN: 0022-2623

PB American Chemical Society

DT Journal

LA English

CC 27-6 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 28, 75

- AB A series of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids, e.g. I, that showed potent agonist activity against RXR $\alpha$  were synthesized via a structure-based design approach. Among the compds. studied, I showed not only very good potency against RXR $\alpha$  ( $K_i$  = 6 nM) but was also found to be greater than 167-fold selective vs RAR $\alpha$  ( $K_i$  > 1000 nM). This compound profiled out as a full agonist in a cell-based transient transfection assay ( $EC_{50}$  = 3 nM). The two antipodes were separated via chiral chromatog., and one was found to be 40-fold more potent than the other. Interestingly, cocrystn. of I with the RXR $\alpha$  protein generated a liganded structure whereby the (S)-antipode was found in the binding pocket. Given orally in db/db mice or ZDF rats, I showed a significant glucose-lowering effect and an increase in liver mass. Triglycerides decreased significantly in db/db mice but increased in the ZDF rats. A dose-dependent decrease of nonesterified free fatty acids was seen in ZDF rats but not in db/db mice. These differences indicate a species specific effect of RXR agonists on lipid metabolism
- ST tetrahydrobenzofuranyl propenoic acid prepn retinoid X receptor agonist MSBAR; tetrahydrobenzothienyl propenoic acid prepn retinoid X receptor agonist MSBAR; antidiabetic agent tetrahydrobenzofuranyl tetrahydrobenzothienyl propenoic acid; antihyperglycemic activity lipid effect liver tetrahydrobenzofuranyl tetrahydrobenzothienyl propenoic acid; Complex tetrahydrobenzofuranylpropenoic acid RXR PPAR heterodimer crystal mol structure
- IT INDEXING IN PROGRESS
- IT Retinoic acid receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RAR- $\alpha$ ; prepn.of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids as antidiabetics and selective RXR $\alpha$  agonists verse RAR $\alpha$ )
- IT Retinoid X receptors  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(RXR $\alpha$ ; prepn.of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids as antidiabetics and selective RXR $\alpha$  agonists verse RAR $\alpha$ )
- IT Structure-activity relationship  
(agonist activity against RXR $\alpha$ ; preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT Heterocyclic compounds  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(five-membered; preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT Lipids  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(metabolism, lipid effect; of Complex of tetrahydrobenzofuranyl propenoic acid with RXR $\alpha$ :PPAR $\gamma$  heterodimer)
- IT Crystal structure  
Molecular structure  
(of Complex of tetrahydrobenzofuranyl propenoic acid with RXR $\alpha$ :PPAR $\gamma$  heterodimer)
- IT Antidiabetic agents  
Diabetes mellitus  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic



- acids)
- IT Carboxylic acids  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
( $\alpha,\beta$ -unsatd.; preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 675580-33-3D, Complex with RXR $\alpha$ :PPAR $\gamma$  heterodimer  
RL: FMU (Formation, unclassified); PRP (Properties); FORM (Formation, nonpreparative)  
(crystal structure; preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 675580-34-4P  
RL: BYP (Byproduct); PREP (Preparation)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 675579-94-9P  
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 503620-55-1P 675579-95-0P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 503620-58-4P 675579-71-2P 675579-96-1P 675579-97-2P  
675579-98-3P 675579-99-4P 675580-02-6P 675580-03-7P 675580-04-8P  
675580-08-2P 675580-17-3P 675580-30-0P 675580-32-2P 675580-37-7P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 675580-35-5P 675580-36-6P  
RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 498-60-2 867-13-0 1899-24-7 2295-31-0 6947-94-0 13414-95-4  
16806-93-2 27452-17-1 78191-00-1 96683-92-0 119999-22-3  
168082-41-5 169126-63-0 170100-73-9 201024-63-7  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)
- IT 220796-18-9P 503621-20-3P 503621-21-4P 503621-28-1P 503621-29-2P  
503621-30-5P 503621-31-6P 675579-69-8P 675579-70-1P  
675579-72-3P 675579-73-4P 675579-74-5P 675579-75-6P 675579-76-7P  
675579-77-8P 675579-78-9P 675579-79-0P 675579-80-3P 675579-81-4P  
675579-82-5P 675579-83-6P 675579-84-7P 675579-85-8P 675579-86-9P  
675579-87-0P 675579-88-1P 675579-89-2P 675579-90-5P 675579-91-6P  
675579-92-7P 675579-93-8P 675580-00-4P 675580-01-5P 675580-05-9P  
675580-06-0P 675580-07-1P 675580-09-3P 675580-10-6P 675580-11-7P  
675580-13-9P 675580-14-0P 675580-15-1P 675580-16-2P 675580-20-8P  
675580-22-0P 675580-24-2P 675580-26-4P 675580-28-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Accelrys Inc; InsightII, Discover, CNX, and Quanta
- (2) Allenby, G; Proc Natl Acad Sci U S A 1993, V90, P30 HCAPLUS
- (3) Beard, R; J Med Chem 1996, V39, P3556 HCAPLUS
- (4) Bell, M; WO 02072528 2002 HCAPLUS
- (5) Boehm, M; J Med Chem 1994, V37, P2930 HCAPLUS
- (6) Boehm, M; J Med Chem 1994, V37, P408 HCAPLUS
- (7) Boehm, M; J Med Chem 1995, V38, P3146 HCAPLUS
- (8) Bourguet, W; Nature 1995, V375, P377 HCAPLUS
- (9) Bourguet, W; Nature 1995, V375, P377 HCAPLUS
- (10) Brunger, A; Acta Crystallogr D 1998, V54, P905
- (11) Canan, K; J Med Chem 1996, V39, P3229
- (12) Canan, K; J Med Chem 1999, V42, P742
- (13) Canan-Koch, S; WO 9712853 1997 HCAPLUS
- (14) Cesario, R; Mol Endocrinol 2001, V15, P1360 HCAPLUS
- (15) Cesario, R; Mol Endocrinol 2001, V15, P1360 HCAPLUS
- (16) Cha, B; Diabetologia 2001, V44, P444 HCAPLUS
- (17) Collaborative Computational Project Number 4; Acta Crystallogr 1994, VD50, P760
- (18) Dawson, M; Bioorg Med Chem Lett 2000, V10, P1307 HCAPLUS
- (19) Dawson, M; Curr Med Chem 2002, V9, P623 HCAPLUS
- (20) Dawson, M; J Med Chem 1995, V38, P3368 HCAPLUS
- (21) Ebisawa, M; Chem Pharm Bull 1999, V47, P1778 HCAPLUS
- (22) Farmer, L; Bioorg Med Chem Lett 2003, V13, P261 HCAPLUS
- (23) Faul, M; Curr Opin Drug Discovery Dev 2002, V5, P974 HCAPLUS
- (24) Freedman, L; Cell 1999, V97, P5 HCAPLUS
- (25) Gampe, R; Mol Cell 2000, V5, P545 HCAPLUS
- (26) Gardinier, K; WO 02071827 2002 HCAPLUS
- (27) Giguere, V; Endocr Rev 1994, V15, P61 HCAPLUS
- (28) Giguere, V; Nature 1987, V330, P624 HCAPLUS
- (29) Grese, T; WO 03007950 2003 HCAPLUS
- (30) Harvat, B; Handbook Exp Pharmacol 1999, V139, P239 HCAPLUS
- (31) Henke, B; J Med Chem 1998, V41, P5020 HCAPLUS
- (32) Heyman, R; Cell 1992, V68, P397 HCAPLUS
- (33) Heyman, R; Cell 1992, V68, P397 HCAPLUS
- (34) Hibi, S; J Med Chem 1998, V41, P3245 HCAPLUS
- (35) Kagechika, H; Curr Med Chem 2002, V9, P591 HCAPLUS
- (36) Lambert, M; Practical Application of Computer-Aided Drug Design 1997, P243 HCAPLUS
- (37) Lee, Y; Heterocycles 1998, V48, P875 HCAPLUS
- (38) Lehmann, J; J Biol Chem 1995, V270, P12953 HCAPLUS
- (39) Lenhard, J; Arterioscler, Thromb, Vasc Biol 2000, V20, P2625 HCAPLUS
- (40) Lenhard, J; Diabetologia 1999, V42, P545 HCAPLUS
- (41) Lenhard, J; Receptors Channels 2001, V7, P249 HCAPLUS
- (42) Levin, A; Nature 1992, V355, P359 HCAPLUS
- (43) Levin, A; Nature 1992, V355, P359 HCAPLUS
- (44) Linney, E; Current Topics in Developmental Biology 1992, P309 HCAPLUS
- (45) Liu, S; Endocrinology 2002, V143, P2880 HCAPLUS
- (46) Liu, Y; Int J Obes Relat Metab Disord 2000, V24, P997 HCAPLUS
- (47) Mangelsdorf, D; Cell 1991, V66, P555 HCAPLUS
- (48) Mangelsdorf, D; Cell 1995, V83, P841 HCAPLUS
- (49) Mangelsdorf, D; Genes Dev 1992, V6, P329 HCAPLUS
- (50) Mangelsdorf, D; Nature 1990, V345, P224 HCAPLUS
- (51) Michellys, P; J Med Chem 2003, V46, P2683 HCAPLUS
- (52) Michellys, P; J Med Chem 2003, V46, P4087 HCAPLUS
- (53) Mukherjee, R; Nature 1997, V386, P407 HCAPLUS
- (54) Navaza, J; Acta Crystallogr 1994, VA50, P157 HCAPLUS

- (55) Nichols, J; Anal Biochem 1998, V257, P112 HCAPLUS
- (56) Nolte, R; Nature 1998, V395, P137 HCAPLUS
- (57) Orfanos, C; Drugs 1987, V34, P459 HCAPLUS
- (58) Otwinowski, Z; Methods Enzymol 1997, V276, P307 HCAPLUS
- (59) Paterniti, J; Nutrition, Genetics and Obesity: Pennington Center Nutrition Series 1999, V9, P477 HCAPLUS
- (60) Paulik, M; Cell Tissue Res 1997, V290, P79 HCAPLUS
- (61) Petrovich, M; Nature 1987, V330, P444
- (62) Pymol; www.pymol.org
- (63) Qing, F; J Chem Soc, Perkin Trans 1 1997, V20, P3053
- (64) Rastinejad, F; Curr Opin Struct Biol 2001, V11, P33 HCAPLUS
- (65) Redfern, C; Adv Organ Biol 1997, V3, P35 HCAPLUS
- (66) Renaud, J; Nature 1995, V378, P681 HCAPLUS
- (67) Schneider, C; J Chem Soc, Perkin Trans 1 1986, P877 HCAPLUS
- (68) Schulman, D; Handbook Exp Pharmacol 1999, V139, P215
- (69) Sherman, S; N Engl J Med 1999, V340, P1075 HCAPLUS
- (70) Sporn, M; The Retinoids: Biology, Chemistry, and Medicine, 2nd ed 1994
- (71) Standeven, A; Biochem Pharm 1997, V54, P517 HCAPLUS
- (72) Takahashi, B; J Med Chem 2002, V45, P3327 HCAPLUS
- (73) Vu-Dac, N; J Clin Invest 1998, V102, P625 HCAPLUS
- (74) Vuligonda, V; Bioorg Med Chem Lett 1996, V6, P213 HCAPLUS
- (75) Vuligonda, V; Bioorg Med Chem Lett 1999, V9, P589 HCAPLUS
- (76) Willson, T; J Med Chem 1996, V39, P665 HCAPLUS
- (77) Wood, T; US 3499751 1970 HCAPLUS
- (78) Xu, H; Mol Cell 1999, V3, P397 HCAPLUS

IT INDEXING IN PROGRESS


IT 675579-71-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)

RN 675579-71-2 HCAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-furanyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 675579-70-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation, agonist activity against RXR $\alpha$ , antidiabetic activity and MSBAR of tetrahydrobenzofuranyl and tetrahydrobenzothienyl propenoic acids)

RN 675579-70-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-furanyl]-, ethyl ester, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L48 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2002:675140 HCAPLUS  
 DN 138:137101  
 ED Entered STN: 06 Sep 2002  
 TI Structure-Activity relationships of novel anti-Malarial agents. Part 4:  
 N-(3-Benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid  
 amides  
 AU Wiesner, Jochen; Mitsch, Andreas; Wissner, Pia; Kramer, Oliver; Jomaa,  
 Hassan; Schlitzer, Martin  
 CS Biochemisches Institut der Universitätsklinik Giessen, Giessen, D-35249,  
 Germany  
 SO Bioorganic & Medicinal Chemistry Letters (2002), 12(19), 2681-2683  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PB Elsevier Science Ltd.  
 DT Journal  
 LA English  
 CC 27-6 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1  
 OS CASREACT 138:137101  
 AB In a previous report, novel anti-malarial compds. based on a  
 2,5-diaminobenzophenone scaffold were described. Here, acryloyl derivs.  
 carrying a biaryl structure consisting of a terminal aryl residue and a  
 central 2-furyl ring were investigated. Several compds. were obtained in  
 the series of para-substituted phenylfurylacryloyl derivs. that displayed  
 improved anti-malarial activity in comparison to earlier described derivs.  
 From the structure-activity relationships it can be deduced that there has  
 to be a lipophilic moiety in the para-position of the terminal Ph residue.  
 Furthermore, there are indications that, alternatively, activity may  
 benefit from the presence of a polar moiety with hydrogen bond acceptor  
 properties.  
 ST acryloyl deriv biaryl furyl prepn; antimalarial acryloyl deriv prepn;  
 benzoyltolylacetylaminophenyl aryl furyl acrylic acid amide prepn  
 IT Structure-activity relationship  
 (antimalarial; preparation of biaryl acryloyl derivs. from 5-bromofurfural  
 and evaluation of antimalarial activity)  
 IT Antimalarials  
 (preparation of biaryl acryloyl derivs. from 5-bromofurfural and evaluation  
 of antimalarial activity)  
 IT 493037-15-3P 493037-16-4P **493037-17-5P** 493037-18-6P  
 493037-19-7P 493037-20-0P **493037-21-1P** 493037-22-2P  
 493037-23-3P 493037-24-4P 493037-25-5P 493037-26-6P 493037-27-7P  
 493037-28-8P 493037-29-9P 493037-30-2P 493037-31-3P 493037-32-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
 (Biological study); PREP (Preparation)  
 (preparation of biaryl acryloyl derivs. from 5-bromofurfural and evaluation  
 of antimalarial activity)  
 IT 98-80-6 1679-18-1 1765-93-1 1899-24-7 2156-04-9 5467-74-3  
 5570-19-4 5720-05-8 5720-07-0 13331-27-6 13922-41-3 22237-13-4  
 24067-17-2 32316-92-0 63139-21-9 98546-51-1 123324-71-0  
 139301-27-2 186497-67-6  
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of biaryl acryloyl derivs. from 5-bromofurfural and evaluation of antimalarial activity)

IT 141-82-2, Malonic acid, reactions 265648-28-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reactant)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Ancelin, M; Blood 1998, V91, P1
- (2) Bohm, M; J Med Chem 2001, V44, P3117 MEDLINE
- (3) Desjardins, R; Antimicrob Agents Chemother 1979, V16, P710 HCAPLUS
- (4) Moriguchi, I; Chem Pharm Bull 1992, V40, P127 HCAPLUS
- (5) Ridley, R; Nature 2002, V415, P686 HCAPLUS
- (6) Sachs, J; Nature 2002, V415, P680 HCAPLUS
- (7) Sakowski, J; J Med Chem 2001, V44, P2886 HCAPLUS
- (8) Shin, S; Bioorg Med Chem Lett 2001, V11, P165 HCAPLUS
- (9) Trager, W; Science 1976, V193, P673 MEDLINE
- (10) Wiesner, J; Bioorg Med Chem 2001, V9, P785 HCAPLUS
- (11) Wiesner, J; Bioorg Med Chem Lett 2001, V11, P423 HCAPLUS

IT 493037-17-5P 493037-21-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL  
(Biological study); PREP (Preparation)

(preparation of biaryl acryloyl derivs. from 5-bromofurfural and evaluation of antimalarial activity)

RN 493037-17-5 HCAPLUS

CN Benzeneacetamide, N-[2-benzoyl-4-[[[(2E)-3-[5-(2-naphthalenyl)-2-furanyl]-1-oxo-2-propenyl]amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 493037-21-1 HCAPLUS

CN Benzeneacetamide, N-[2-benzoyl-4-[[[(2E)-3-[5-[4-(1,1-dimethylethyl)phenyl]-2-furanyl]-1-oxo-2-propenyl]amino]phenyl]-4-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



- L48 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 2000:338368 HCAPLUS  
 DN 133:135199  
 ED Entered STN: 23 May 2000  
 TI Facile Synthesis of Oxa- and Azacyclic Dienes via Cycloalkenation of Alkynyltungsten Compounds. Stereoselective Construction of Tricyclic Furan and Pyran Derivatives via Intramolecular Diels-Alder Reaction  
 AU Li, Wen-Tai; Pan, Min-Hui; Wu, Yi-Ru; Wang, Sue-Lein; Liao, Fen-Lin; Liu, Rai-Shung  
 CS Department of Chemistry, National Tsing-Hua University, Hsinchu, Taiwan  
 SO Journal of Organic Chemistry (2000), 65(12), 3761-3766  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 CC 27-14 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 29  
 OS CASREACT 133:135199  
 AB A convenient and short synthesis of functionalized oxacyclic and azacyclic dienes is developed on the basis of organotungsten chemical Alkynyltungsten compds. bearing a tethered alc. and amine are treated with aldehydes and BF<sub>3</sub>.Et<sub>2</sub>O in cold di-Et ether to give tungsten-heterocyclic carbenium salts, further leading to tungsten-heterocyclic dienes via deprotonation with Et<sub>3</sub>N. Hydrodemetalation of these tungsten-heterocyclic dienes is performed by the action of anhydrous Me<sub>3</sub>NO in MeCN. This method is applicable to the synthesis of a number of oxa- and azacyclic dienes, including those tethered with an electron-deficient olefin. The oxacyclic 1,3,8-nonatrienes and 1,3,9-decatrienes undergo intramol. Diels-Alder reactions upon heating in toluene, yielding tricyclic tetrahydropyran and -furan derivs. with excellent diastereoselectivities.  
 ST pyran tetrahydro tricyclic prepn; furan tetrahydro tricyclic prepn; pyrrole alkenyl prepn; tungsten furyl pyranyl pyrrolyl prepn demetalation; alkynyltungsten reaction aldehyde  
 IT Diels-Alder reaction  
 (intramol.; stereoselective preparation of tricyclic furans and pyran via cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder reaction)  
 IT Cyclocondensation reaction  
 (stereoselective preparation of tricyclic furans and pyran via cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder reaction)  
 IT Heterocyclic compounds  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (stereoselective preparation of tricyclic furans and pyran via cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder reaction)

IT 285565-50-6P 285565-61-9P 285565-62-0P 285565-63-1P 285565-64-2P  
285565-65-3P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective preparation of tricyclic furans and pyran via  
cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder  
reaction)

IT 108-31-6, Maleic anhydride, reactions 541-59-3, Maleimide 624-48-6,  
Dimethyl maleate 941-69-5 1423-60-5, 3-Butyn-2-one 12128-24-4  
190448-89-6 205755-53-9 285565-39-1 285565-55-1 285565-67-5  
285565-68-6 286426-97-9 286426-98-0 286426-99-1 286427-00-7  
286427-01-8 286427-03-0 286427-11-0

RL: RCT (Reactant); RACT (Reactant or reagent)  
(stereoselective preparation of tricyclic furans and pyran via  
cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder  
reaction)

IT 285565-43-7P 285565-56-2P 285565-57-3P 285565-58-4P 285565-59-5P  
285565-60-8P 286426-93-5P 286426-95-7P 286426-96-8P 286427-05-2P  
286427-08-5P 286427-10-9P 286427-13-2P 286427-14-3P 286427-16-5P  
286427-17-6P 286427-19-8P 286427-20-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(stereoselective preparation of tricyclic furans and pyran via  
cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder  
reaction)

IT 285565-40-4P 285565-41-5P 285565-42-6P 285565-44-8P 285565-45-9P  
285565-46-0P 285565-47-1P 285565-48-2P 285565-49-3P 285565-51-7P  
285565-52-8P 285565-53-9P 285565-54-0P **285565-66-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective preparation of tricyclic furans and pyran via  
cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder  
reaction)

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Aelterman, W; Tetrahedron 1998, V54, P2563 HCAPLUS
- (2) Bigogno, C; Heterocycles 1995, V41, P973 HCAPLUS
- (3) Boeckman, R; J Am Chem Soc 1988, V110, P8250 HCAPLUS
- (4) Boeckman, R; Tetrahedron 1997, V53, P8941 HCAPLUS
- (5) Breitmaier, E; Chem Ber 1986, V119, P3204
- (6) Breitmaier, E; Synthesis 1986, P584
- (7) Breitmaier, E; Synthesis 1989, P623
- (8) Brosius, A; J Am Chem Soc 1999, V121, P700 HCAPLUS
- (9) Brown, F; Tetrahedron Lett 1985, V26, P2297 HCAPLUS
- (10) Burke, S; Tetrahedron Lett 1984, V25, P19 HCAPLUS
- (11) Burke, S; Tetrahedron Lett 1988, V29, P2757 HCAPLUS
- (12) Cornwall, P; J Chem Soc, Perkin Trans 1 1993, P2395 HCAPLUS
- (13) Hashimoto, S; J Am Chem Soc 1988, V110, P3760
- (14) Ichihara, A; Tetrahedron Lett 1987, V28, P1175 HCAPLUS
- (15) Li, W; J Am Chem Soc 1998, V120, P4520 HCAPLUS
- (16) Liang, K; J Am Chem Soc 1997, V119, P4404 HCAPLUS
- (17) Liang, K; J Org Chem 1998, V63, P7289 HCAPLUS
- (18) Marshall, J; J Am Chem Soc 1988, V110, P1290
- (19) Marshall, J; J Org Chem 1984, V49, P5277 HCAPLUS
- (20) Matikainen, J; Tetrahedron Lett 1988, V29, P2685 HCAPLUS
- (21) Roush, W; Comprehensive Organic Synthesis 1991, V5, P513
- (22) Roush, W; Tetrahedron Lett 1987, V28, P2447 HCAPLUS
- (23) Trost, B; J Am Chem Soc 1984, V106, P7641 HCAPLUS
- (24) Wu, T; Tetrahedron Lett 1985, V26, P2293 HCAPLUS


IT **285565-66-4P**

RL: SPN (Synthetic preparation); PREP (Preparation)  
(stereoselective preparation of tricyclic furans and pyran via  
cycloalkenation of alkynyltungsten compds. and intramol. Diels-Alder  
reaction)

RN 285565-66-4 HCAPLUS

CN Furan, 2,3-dihydro-2-(2-naphthalenyl)-4-(1E)-1-propenyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L48 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1999:421672 HCAPLUS  
 DN 131:73571  
 ED Entered STN: 08 Jul 1999  
 TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as MCP-1 receptor antagonists.  
 IN Shiraishi, Mitsuru; Kitayoshi, Takahito; Aramaki, Yoshio; Honda, Susumu; Oda, Tsuneo  
 PA Takeda Chemical Industries, Ltd., Japan  
 SO PCT Int. Appl., 513 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C07D295-12  
 ICS A61K031-16; A61K031-33; A61K031-66; C07C233-62; C07D213-20; C07D213-61; C07D213-84; C07D213-85; C07F009-44; C07F009-54; C07F009-6584; C07F009-6568; C07F009-655; C07F009-53; C07D313-08; C07D407-12  
 CC 27-21 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1, 25, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932468	A1	19990701	WO 1998-JP5707	19981217
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 9813686	A	20001010	BR 1998-13686	19981212
CA 2311428	AA	19990701	CA 1998-2311428	19981217
AU 9916830	A1	19990712	AU 1999-16830	19981217
AU 742077	B2	20011213		
ZA 9811576	A	20000619	ZA 1998-11576	19981217
EP 1040103	A1	20001004	EP 1998-961383	19981217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6166006	A	20001226	US 1998-213379	19981217
JP 11263764	A2	19990928	JP 1998-360780	19981218
NO 2000003133	A	20000809	NO 2000-3133	20000616
US 6413947	B1	20020702	US 2000-661194	20000913
PRAI JP 1997-351481	A	19971219		
US 1998-213379	A3	19981217		
WO 1998-JP5707	W	19981217		



OS MARPAT 131:73571  
GI



- AB Title compds. I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered aromatic ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)KR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group], were prepared Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). II at 1  $\mu$ M inhibited MCP-1 induced chemotaxis in CHO cells by 89%. A II capsule composition is given.
- ST benzoxepinecarboxamide prepn monocyte chemoattractant protein receptor antagonist; benzocycloheptenecarboxamide prepn monocyte chemoattractant protein receptor antagonist; naphthalenecarboxamide prepn monocyte chemoattractant protein receptor antagonist; myocarditis treatment benzoxepinecarboxamide benzocycloheptenecarboxamide naphthalenecarboxamide; cardiac infarction treatment benzoxepinecarboxamide benzocycloheptenecarboxamide naphthalenecarboxamide
- IT Monocyte chemoattractant protein-1  
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(antagonists; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- IT Heart, disease  
(infarction, treatment; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- IT Chemokine receptors  
Chemokine receptors  
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(monocyte chemoattractant protein-1; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- IT Heart, disease  
(myocarditis, treatment; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- IT 229003-88-7P 229004-17-5P 229004-21-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides,

naphthalenecarboxamides, and related compds. as MCP-1 receptor  
antagonists)

IT	229003-36-5P	229003-37-6P	229003-38-7P	229003-39-8P	229003-40-1P
	229003-41-2P	229003-42-3P	229003-43-4P	229003-44-5P	229003-45-6P
	229003-46-7P	229003-47-8P	229003-48-9P	229003-49-0P	229003-50-3P
	229003-51-4P	229003-52-5P	229003-53-6P	229003-54-7P	229003-55-8P
	229003-56-9P	229003-57-0P	229003-58-1P	229003-59-2P	229003-60-5P
	229003-61-6P	229003-62-7P	229003-63-8P	229003-64-9P	229003-65-0P
	229003-66-1P	229003-67-2P	229003-68-3P	229003-69-4P	229003-70-7P
	229003-71-8P	229003-72-9P	229003-73-0P	229003-74-1P	229003-75-2P
	229003-76-3P	229003-77-4P	229003-78-5P	229003-79-6P	229003-80-9P
	229003-81-0P	229003-82-1P	229003-83-2P	229003-84-3P	229003-85-4P
	229003-86-5P	229003-87-6P	229003-89-8P	229003-90-1P	229003-91-2P
	229003-92-3P	229003-93-4P	229003-94-5P	229003-95-6P	229003-96-7P
	229003-97-8P	229003-98-9P	229003-99-0P	229004-00-6P	229004-01-7P
	229004-02-8P	229004-03-9P	229004-04-0P	229004-05-1P	229004-06-2P
	229004-07-3P	229004-08-4P	229004-09-5P	229004-10-8P	229004-11-9P
	229004-12-0P	229004-13-1P	229004-14-2P	229004-15-3P	229004-16-4P
	229004-18-6P	229004-19-7P	229004-20-0P	229004-22-2P	229004-23-3P
	229004-24-4P	229004-25-5P	229004-26-6P	229004-27-7P	229004-28-8P
	229004-29-9P	229004-30-2P	229004-31-3P	229004-32-4P	229004-33-5P
	229004-34-6P	229004-35-7P	229004-36-8P	229004-37-9P	229004-38-0P
	229004-39-1P	229004-40-4P	229004-41-5P	229004-42-6P	229004-43-7P
	229004-44-8P	229004-45-9P	229004-46-0P	229004-47-1P	229004-48-2P
	229004-49-3P	229004-50-6P	229004-51-7P	229004-52-8P	229004-53-9P
	229004-54-0P	229004-55-1P	229004-56-2P	229004-57-3P	229004-58-4P
	229004-59-5P	229004-60-8P	229004-61-9P	229004-62-0P	229004-63-1P
	229004-64-2P	229004-65-3P	229004-66-4P	229004-67-5P	229004-68-6P
	229004-69-7P	229004-70-0P	229004-71-1P	229004-72-2P	229004-73-3P
	229004-74-4P	229004-75-5P	229004-76-6P	229004-77-7P	229004-78-8P
	229004-79-9P	229004-80-2P	229004-81-3P	229004-82-4P	229004-83-5P
	229004-84-6P	229004-85-7P	229004-86-8P	229004-87-9P	229004-88-0P
	229004-89-1P	229004-90-4P	229004-91-5P	229004-92-6P	229004-93-7P
	229004-94-8P	229004-95-9P	229004-96-0P	229004-97-1P	229004-98-2P
	229004-99-3P	229005-00-9P	229005-01-0P	229005-02-1P	229005-03-2P
	229005-04-3P	229005-05-4P	229005-06-5P	229005-07-6P	229005-08-7P
	229005-09-8P	229005-10-1P	229005-11-2P	229005-12-3P	229005-13-4P
	229005-14-5P	229005-15-6P	229005-16-7P	229005-17-8P	229005-18-9P
	229005-19-0P	229005-20-3P	229005-21-4P	229005-22-5P	229005-23-6P
	229005-24-7P	229005-25-8P	229005-26-9P	229005-27-0P	229005-28-1P
	229005-29-2P	229005-30-5P	229005-31-6P	229005-32-7P	229005-33-8P
	229005-34-9P	229005-35-0P	229005-36-1P	229005-37-2P	229005-38-3P
	229005-39-4P	229005-40-7P	229005-41-8P	229005-42-9P	229005-43-0P
	229005-44-1P	229005-45-2P	229005-46-3P	229005-47-4P	229005-48-5P
	229005-49-6P	229005-50-9P	229005-51-0P	229005-52-1P	229005-53-2P
	229005-54-3P	229005-55-4P	229005-56-5P	229005-57-6P	229005-58-7P
	229005-59-8P	229005-60-1P	229005-61-2P	229005-62-3P	229005-63-4P
	229005-64-5P	229005-65-6P	229005-66-7P	229005-67-8P	229005-68-9P
	229005-69-0P	229005-70-3P	229005-71-4P	229005-72-5P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT	229005-73-6P	229005-74-7P	229005-75-8P	229005-76-9P	229005-77-0P
	229005-78-1P	229005-79-2P	229005-80-5P	229005-81-6P	229005-82-7P
	229005-83-8P	229005-84-9P	229005-85-0P	229005-86-1P	229005-87-2P
	229005-88-3P	229005-89-4P	229005-90-7P	229005-91-8P	229005-92-9P
	229005-93-0P	229005-94-1P	229005-95-2P	229005-96-3P	229005-97-4P
	229005-98-5P	229005-99-6P	229006-00-2P	229006-01-3P	
	229006-02-4P	229006-03-5P	229006-04-6P	229006-05-7P	
	229006-06-8P	229006-07-9P	229006-08-0P	229006-09-1P	

229006-10-4P 229006-11-5P **229006-12-6P** 229006-13-7P  
 229006-14-8P 229006-15-9P 229006-16-0P 229006-17-1P 229006-18-2P  
 229006-19-3P 229006-20-6P 229006-21-7P 229006-22-8P 229006-23-9P  
 229006-24-0P 229006-25-1P 229006-26-2P 229006-27-3P 229006-28-4P  
 229006-29-5P 229006-30-8P 229006-31-9P 229006-32-0P 229006-33-1P  
 229006-34-2P 229006-35-3P 229006-36-4P 229006-37-5P 229006-38-6P  
 229006-39-7P 229006-40-0P 229006-41-1P 229006-42-2P 229006-43-3P  
 229006-44-4P 229006-45-5P 229006-46-6P 229006-47-7P 229006-48-8P  
 229006-49-9P 229006-50-2P 229006-51-3P 229006-52-4P 229006-53-5P  
 229009-44-3P 229009-45-4P 229009-46-5P 229009-47-6P 229153-64-4P  
 229153-65-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT 75-64-9, tert-Butylamine, reactions 76-05-1, reactions 78-67-1  
 96-22-0, 3-Pentanone 96-97-9 98-53-3, 4-tert-Butylcyclohexanone  
 99-98-9, 4-Dimethylaminoaniline 100-11-8, 4-Nitrobenzylbromide  
 100-14-1, 4-Nitrobenzylchloride 100-48-1, 4-Cyanopyridine 100-54-9,  
 3-Cyanopyridine 100-60-7, N-Cyclohexyl-N-methylamine 100-61-8,  
 N-Methylaniline, reactions 100-76-5, Quinuclidine 102-69-2,  
 Tripropylamine 103-67-3, N-Methylbenzylamine 103-76-4,  
 1-(2-Hydroxyethyl)piperazine 106-41-2, 4-Bromophenol 106-53-6,  
 4-Bromothiophenol 107-08-4 107-15-3, 1,2-Ethanediamine, reactions  
 108-94-1, Cyclohexanone, reactions 108-99-6, 3-Picoline 109-01-3,  
 1-Methylpiperazine 109-04-6, 2-Bromopyridine 109-06-8, 2-Picoline  
 110-52-1, 1,4-Dibromobutane 110-68-9, N-Methyl-N-butylamine 110-87-2  
 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions  
 111-24-0, 1,5-Dibromopentane 111-33-1 111-42-2, reactions 111-49-9  
 111-96-6, Bis(2-methoxyethyl)ether 120-92-3, Cyclopentanone 121-44-8,  
 reactions 122-00-9 123-75-1, Pyrrolidine, reactions 123-90-0,  
 Thiomorpholine 288-47-1, Thiazole 358-23-6, Trifluoromethanesulfonic  
 acid anhydride 407-14-7, 4-Trifluoromethoxybromobenzene 462-08-8,  
 3-Aminopyridine 497-38-1, Norcamphor 502-42-1, Cycloheptanone  
 534-03-2, 2-Amino-1,3-propanediol 536-78-7, 3-Ethylpyridine 539-88-8,  
 Ethyl levulinate 555-16-8, 4-Nitrobenzaldehyde, reactions 585-70-6,  
 5-Bromo-2-furancarboxylic acid 588-96-5, 4-Bromophenetole 591-22-0,  
 3,5-Lutidine 591-49-1, 1-Methylcyclohexene 616-44-4 617-05-0, Ethyl  
 vanillate 617-27-6 619-23-8, 3-Nitrobenzyl chloride 619-73-8,  
 4-Nitrobenzylalcohol 620-87-1, 2-(4-Nitrobenzyl)pyridine 625-43-4,  
 N-Methylisobutylamine 626-60-8, 3-Chloropyridine 626-67-5,  
 1-Methylpiperidine 765-58-2, 5-Bromo-2-methylthiophene 766-09-6,  
 1-Ethylpiperidine 766-97-2, 4-Methylphenylacetylene 771-99-3,  
 4-Phenylpiperidine 841-77-0, 1-Benzhydrylpiperazine 930-69-8, Sodium  
 phenylsulfide 998-40-3, Tributylphosphine 1003-09-4, 2-Bromothiophene  
 1072-72-6, 4H-Tetrahydrothiopyran-4-one 1080-32-6, Diethyl  
 benzylphosphonate 1121-92-2 1205-62-5, 4-Nitrobenzylphosphonic acid  
 1450-75-5 1484-84-0, 2-(2-Hydroxyethyl)piperidine 1585-07-5,  
 4-Ethylbromobenzene 1663-39-4 1679-18-1, 4-Chlorophenylboronic acid  
 1692-15-5 1722-12-9, 2-Chloropyrimidine 1761-61-1,  
 5-Bromosalicylaldehyde 1765-93-1, 4-Fluorophenylboronic acid  
 2320-30-1, 3,5-Dimethylcyclohexanone 2338-18-3 2605-67-6 2635-13-4  
 2969-81-5, Ethyl-4-bromobutyrate 3132-99-8, 3-Bromobenzaldehyde  
 3218-02-8, Amino-methylcyclohexane 3287-99-8, Benzylamine hydrochloride  
 3433-37-2, 2-Piperidinemethanol 3490-06-0 3492-64-6 4068-76-2,  
 Methyl-5-bromosalicylate 4606-65-9, 3-(Hydroxymethyl)piperidine  
 4701-17-1, 5-Bromo-2-thiophenecarboxaldehyde 4746-97-8,  
 1,4-Cyclohexanedione monoethyleneketal 5105-78-2 5205-39-0  
 5332-73-0, 3-Methoxypropylamine 5339-26-4, 4-(2-Bromoethyl)nitrobenzene  
 5382-16-1, 4-Hydroxypiperidine 5459-93-8, N-Ethylcyclohexylamine  
 5466-06-8, Ethyl 3-mercaptopropionate 5720-05-8, 4-Methylphenylboronic

acid 5794-88-7, 5-Bromoanthranilic acid 6165-69-1 6291-85-6,  
 3-Ethoxypropylamine 6388-74-5, p-Nitrostyreneoxide 6602-32-0,  
 2-Bromo-3-hydroxypyridine 6638-79-5, N,O-Dimethylhydroxylamine  
 hydrochloride 6836-19-7, 7-Methoxy-1-tetralone 6850-65-3,  
 4-Aminocyclohexanol 6859-99-0, 3-Hydroxypiperidine 10544-63-5, Ethyl  
 crotonate 13331-23-2, 2-Furylboronic acid 13331-27-6,  
 3-Nitrophenylboronic acid 13515-93-0, Sarcosine methyl ester  
 hydrochloride 13623-25-1, 6-Methoxy-1-indanone 13952-84-6,  
 1-Methylpropylamine 15300-97-7 16419-60-6 17857-14-6,  
 (3-Carboxypropyl)triphenylphosphonium bromide 18471-73-3,  
 2-(4-Aminophenyl)pyridine 18600-42-5, p-Nitrobenzylamine hydrochloride  
 18664-32-9, 1,3-Dimethoxyacetone 18791-75-8, 4-Bromo-2-  
 thiophenecarboxaldehyde 20074-79-7, Diethyl 4-aminobenzylphosphonate  
 20826-04-4, 5-Bromonicotinic acid 20980-22-7, 1-(2-Pyrimidyl)piperazine  
 23462-75-1, Tetrahydropyran-3-one 24252-37-7, Ethyl 1-methylpiperidine-4-  
 carboxylate 25808-30-4 28611-39-4 29943-42-8, 4H-Tetrahydropyran-4-  
 one 31252-42-3, 4-Benzylpiperidine 32231-06-4, 1-(3,4-  
 Methylenedioxybenzyl)-piperazine 35386-24-4, 1-(2-  
 Methoxyphenyl)piperazine 38212-30-5, 1-(4-Methoxyphenyl)piperazine  
 50541-93-0, 4-Amino-1-benzylpiperidine 50729-68-5 52146-35-7,  
 1-(3,4,5-Trimethoxybenzyl)piperazine 60548-09-6, 1-(2-Furoyl)piperazine  
 hydrochloride 61081-32-1 73579-08-5, 1-Methyl-4-methylaminopiperidine  
 79099-07-3 80670-21-9 82261-42-5, 3-(4-Aminophenyl)pyridine  
 85199-06-0 87779-78-0 89878-14-8, Diethyl-(3-pyridyl)-borane  
 93777-26-5, 5-Bromo-2-fluorobenzaldehyde 96251-92-2 98546-51-1,  
 4-Methylthiophenylboronic acid 128796-39-4, 4-  
 Trifluoromethylphenylboronic acid 162210-31-3 162271-10-5  
 175394-06-6 186498-02-2 229009-38-5 229009-39-6 229009-40-9  
 229009-41-0 229009-42-1 229009-43-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides,  
 naphthalenecarboxamides, and related compds. as MCP-1 receptor  
 antagonists)

IT 623-04-1P, 4-Aminobenzyl alcohol 955-44-2P 2089-33-0P 2439-56-7P  
 4519-78-2P, Benzyl-diethylphosphine oxide 5339-15-1P 6149-46-8P  
 6406-74-2P 6425-46-3P 6763-91-3P 6881-57-8P, Benzylphosphonic acid  
 14473-91-7P 15084-55-6P 15115-76-1P 15184-96-0P 16341-77-8P  
 17302-46-4P 18483-99-3P 18484-05-4P 20173-88-0P 20712-12-3P  
 22009-38-7P, 7-Hydroxy-1-tetralone 22237-13-4P, 4-Ethoxyphenylboronic  
 acid 24100-18-3P 29124-57-0P 29608-05-7P 34035-05-7P 34160-40-2P  
 38035-10-8P 40594-34-1P 41526-73-2P, 7-Phenyl-1-tetralone  
 42870-65-5P 50534-23-1P 50534-24-2P 51013-67-3P 53678-61-8P  
 54306-15-9P 55008-98-5P 55009-03-5P 55580-07-9P 55580-08-0P  
 56851-32-2P 58498-12-7P 59507-44-7P 59507-46-9P 59719-62-9P  
 62157-62-4P 62803-47-8P, 6-Hydroxy-1-indanone 62806-32-0P  
 63139-21-9P, 4-Ethylphenylboronic acid 73676-23-0P 79432-87-4P  
 79909-21-0P 83619-74-3P 91150-58-2P 91953-92-3P 92033-77-7P  
 93138-55-7P 94839-07-3P 95323-86-7P 98008-66-3P 123324-71-0P,  
 4-tert-Butylphenylboronic acid 131230-76-7P 133851-67-9P  
 135605-97-9P 138007-25-7P 139301-27-2P, 4-  
 Trifluoromethoxyphenylboronic acid 142335-64-6P 143632-57-9P  
 144464-65-3P 145654-38-2P 147539-41-1P 160127-63-9P 162607-15-0P  
 162607-20-7P 168897-21-0P 175393-25-6P 175394-17-9P 175840-02-5P  
 179055-22-2P 183608-47-1P 185111-27-7P 229006-54-6P 229006-55-7P  
 229006-56-8P 229006-57-9P 229006-58-0P 229006-59-1P 229006-60-4P  
 229006-61-5P 229006-62-6P 229006-63-7P 229006-64-8P 229006-65-9P  
 229006-66-0P 229006-67-1P 229006-68-2P 229006-69-3P 229006-70-6P  
 229006-71-7P 229006-72-8P 229006-73-9P 229006-74-0P 229006-75-1P  
 229006-76-2P 229006-77-3P 229006-78-4P 229006-79-5P 229006-80-8P  
 229006-81-9P 229006-82-0P 229006-83-1P 229006-84-2P 229006-85-3P  
 229006-86-4P 229006-87-5P 229006-88-6P 229006-89-7P 229006-90-0P  
 229006-91-1P 229006-92-2P 229006-93-3P 229006-94-4P 229006-95-5P  
 229006-96-6P 229006-97-7P 229006-98-8P 229006-99-9P 229007-00-5P

229007-01-6P	229007-02-7P	229007-03-8P	229007-04-9P	229007-05-0P
229007-06-1P	229007-07-2P	229007-08-3P	229007-09-4P	229007-10-7P
229007-11-8P	229007-12-9P	229007-13-0P	229007-14-1P	229007-15-2P
229007-16-3P	229007-17-4P	229007-18-5P	229007-19-6P	229007-20-9P
229007-21-0P	229007-22-1P	229007-23-2P	229007-24-3P	229007-25-4P
229007-26-5P	229007-27-6P	229007-28-7P	229007-29-8P	229007-30-1P
229007-31-2P	229007-32-3P	229007-33-4P	229007-34-5P	229007-35-6P
229007-36-7P	229007-37-8P	229007-38-9P	229007-39-0P	229007-40-3P
229007-41-4P	229007-42-5P	229007-43-6P	229007-44-7P	229007-45-8P
229007-46-9P	229007-47-0P	229007-48-1P	229007-49-2P	229007-50-5P
229007-51-6P	229007-52-7P	229007-53-8P	229007-54-9P	229007-55-0P
229007-56-1P	229007-57-2P	229007-58-3P	229007-59-4P	229007-60-7P
229007-61-8P	229007-62-9P	229007-63-0P	229007-64-1P	229007-65-2P
229007-66-3P	229007-67-4P	229007-68-5P	229007-69-6P	229007-70-9P
229007-71-0P	229007-72-1P	229007-73-2P	229007-74-3P	229007-75-4P
229007-76-5P	229007-77-6P	229007-78-7P	229007-79-8P	229007-80-1P
229007-81-2P	229007-82-3P	229007-83-4P	229007-84-5P	229007-85-6P
229007-86-7P	229007-87-8P	229007-88-9P	229007-89-0P	229007-90-3P
229007-91-4P	229007-92-5P	229007-93-6P	229007-94-7P	229007-95-8P
229007-96-9P	229007-97-0P	229007-98-1P	229007-99-2P	229008-00-8P
229008-01-9P	229008-02-0P	229008-03-1P	229008-04-2P	229008-05-3P
229008-06-4P	229008-07-5P	229008-09-7P		

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT	229008-11-1P	229008-14-4P	229008-16-6P	229008-18-8P	229008-20-2P
	229008-22-4P	229008-24-6P	229008-26-8P	229008-27-9P	229008-28-0P
	229008-29-1P	229008-30-4P	229008-31-5P	229008-32-6P	229008-33-7P
	229008-34-8P	229008-35-9P	229008-36-0P	229008-37-1P	229008-38-2P
	229008-39-3P	229008-40-6P	229008-41-7P	229008-42-8P	229008-43-9P
	229008-44-0P	229008-45-1P	229008-46-2P	229008-47-3P	229008-48-4P
	229008-49-5P	229008-50-8P	229008-51-9P	229008-52-0P	229008-53-1P
	<b>229008-54-2P</b>	<b>229008-55-3P</b>	<b>229008-56-4P</b>		
	<b>229008-57-5P</b>	229008-58-6P	229008-59-7P	229008-60-0P	
	229008-61-1P	229008-62-2P	229008-63-3P	229008-64-4P	229008-65-5P
	229008-66-6P	229008-67-7P	229008-68-8P	229008-69-9P	229008-70-2P
	229008-71-3P	229008-72-4P	229008-73-5P	229008-74-6P	229008-75-7P
	229008-76-8P	229008-77-9P	229008-78-0P	229008-79-1P	229008-80-4P
	229008-81-5P	229008-82-6P	229008-83-7P	229008-84-8P	229008-85-9P
	229008-86-0P	229008-87-1P	229008-88-2P	229008-89-3P	229008-90-6P
	229008-91-7P	229008-92-8P	229008-93-9P	229008-94-0P	229008-95-1P
	229008-96-2P	229008-97-3P	229008-98-4P	229008-99-5P	229009-00-1P
	229009-01-2P	229009-02-3P	229009-03-4P	229009-04-5P	229009-05-6P
	229009-06-7P	229009-07-8P	229009-08-9P	229009-09-0P	229009-10-3P
	229009-11-4P	229009-12-5P	229009-13-6P	229009-14-7P	229009-15-8P
	229009-16-9P	229009-17-0P	229009-18-1P	229009-19-2P	229009-20-5P
	229009-21-6P	229009-22-7P	229009-23-8P	229009-24-9P	229009-25-0P
	229009-26-1P	229009-27-2P	229009-28-3P	229009-29-4P	229009-30-7P
	229009-31-8P	229009-32-9P	229009-33-0P	229009-34-1P	229009-35-2P
	229009-36-3P	229009-37-4P	229153-66-6P	229153-67-7P	229153-68-8P
	229153-69-9P				

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Teijin Ltd; JP 07025756 A 1995 HCAPLUS

(2) Teijin Ltd; JP 07025757 A 1995 HCAPLUS

IT 229006-01-3P 229006-02-4P 229006-06-8P


**229006-08-0P 229006-12-6P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229006-08-0 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA

INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 HCAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-, iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

● I<sup>-</sup>

IT 229008-54-2P 229008-56-4P 229008-57-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229008-54-2 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)-(9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



L48 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:421562 HCAPLUS

DN 131:87834

ED Entered STN: 08 Jul 1999

TI Preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compounds as CCR5 antagonists.

IN Nishimura, Osamu; Baba, Masanori; Sawada, Hidekazu; Kanzaki, Naoyuki; Kuroshima, Ken-ichi; Shiraishi, Mitsuru; Aramaki, Yoshio

PA Takeda Chemical Industries, Ltd., Japan

SO PCT Int. Appl., 516 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-00

CC 27-21 (Heterocyclic Compounds (One Hetero Atom))

Section cross-reference(s): 1, 25, 63




FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9932100	A2	19990701	WO 1998-JP5708	19981217
WO 9932100	A3	19990910		
W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2304959	AA	19990701	CA 1998-2304959	19981217
AU 9916831	A1	19990712	AU 1999-16831	19981217
AU 748064	B2	20020530		
ZA 9811574	A	20000619	ZA 1998-11574	19981217
EP 1039899	A2	20001004	EP 1998-961384	19981217



R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, FI

BR 9813691	A	20001010	BR 1998-13691	19981217
JP 2000128782	A2	20000509	JP 1998-360820	19981218
US 6096780	A	20000801	US 1999-377040	19990819
US 6376536	B1	20020423	US 2000-580270	20000526
NO 2000003179	A	20000619	NO 2000-3179	20000619
US 6268354	B1	20010731	US 2000-661320	20000913
PRAI JP 1997-351480	A	19971219		
JP 1998-218875	A	19980803		
JP 1998-234388	A	19980820		
US 1998-104845P	P	19981016		
US 1998-104847P	P	19981116		
US 1998-213377	A3	19981217		
WO 1998-JP5708	W	19981217		
US 1999-377040	A3	19990819		
OS MARPAT 131:87834				
GI				



- AB A pharmaceutical composition for antagonizing CCR5 comprises I [R1 = (substituted) 5-6 membered ring; W = Q1, Q2; A = atoms to form a (substituted) 5-6 membered aromatic ring; X = S, O, (substituted) C, N; B = atoms to form a (substituted) 5-7 membered ring; Z = bond, divalent group; R2 = (substituted) amino, ammonio, heterocyclyl, S-bonded group, P(O)kR5R6; k = 0, 1; R5, R6 = (substituted) hydrocarbyl, amino; PR5R6 = cyclic group]. Thus, 7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxylic acid in CH2Cl2 was treated with (COCl)2 and DMF to give a residue which was stirred with 4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]aniline and Et3N in THF to give N-[4-[N-methyl-N-(tetrahydropyran-4-yl)aminomethyl]phenyl]-7-(4-methylphenyl)-2,3-dihydro-1-benzoxepine-4-carboxamide (II). A II capsule composition is given.
- ST benzoxepinecarboxamide prepn chemokine coreceptor antagonist;  
benzocycloheptenecarboxamide prepn chemokine coreceptor antagonist;  
naphthalenecarboxamide prepn chemokine coreceptor antagonist; AIDS treatment benzoxepinecarboxamide benzocycloheptenecarboxamide naphthalenecarboxamide
- IT Monocyte chemoattractant protein-1  
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(antagonists; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)
- IT Chemokine receptors  
Chemokine receptors  
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
(monocyte chemoattractant protein-1; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT Anti-AIDS agents  
(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT Chemokine receptors  
RL: BPR (Biological process); BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study); PROC (Process)  
( $\beta$  chemokine receptor CCR5; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT Chemokines  
RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)  
( $\beta$ , receptor CCR5; preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT 229003-88-7P 229004-17-5P 229004-21-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT 229003-36-5P 229003-37-6P 229003-38-7P 229003-39-8P 229003-40-1P  
229003-41-2P 229003-42-3P 229003-43-4P 229003-44-5P 229003-45-6P  
229003-46-7P 229003-47-8P 229003-48-9P 229003-49-0P 229003-50-3P  
229003-51-4P 229003-52-5P 229003-53-6P 229003-54-7P 229003-55-8P  
229003-56-9P 229003-57-0P 229003-58-1P 229003-59-2P 229003-60-5P  
229003-61-6P 229003-62-7P 229003-63-8P 229003-64-9P 229003-65-0P  
229003-66-1P 229003-67-2P 229003-68-3P 229003-69-4P 229003-70-7P  
229003-71-8P 229003-72-9P 229003-73-0P 229003-74-1P 229003-75-2P  
229003-76-3P 229003-77-4P 229003-78-5P 229003-79-6P 229003-80-9P  
229003-81-0P 229003-82-1P 229003-83-2P 229003-84-3P 229003-85-4P  
229003-86-5P 229003-87-6P 229003-89-8P 229003-90-1P 229003-91-2P  
229003-92-3P 229003-93-4P 229003-94-5P 229003-95-6P 229003-96-7P  
229003-97-8P 229003-98-9P 229003-99-0P 229004-00-6P 229004-01-7P  
229004-02-8P 229004-03-9P 229004-04-0P 229004-05-1P 229004-06-2P  
229004-07-3P 229004-08-4P 229004-09-5P 229004-10-8P 229004-11-9P  
229004-12-0P 229004-13-1P 229004-14-2P 229004-15-3P 229004-16-4P  
229004-18-6P 229004-19-7P 229004-20-0P 229004-22-2P 229004-23-3P  
229004-24-4P 229004-25-5P 229004-26-6P 229004-27-7P 229004-28-8P  
229004-29-9P 229004-30-2P 229004-31-3P 229004-32-4P 229004-33-5P  
229004-34-6P 229004-35-7P 229004-36-8P 229004-37-9P 229004-38-0P  
229004-39-1P 229004-40-4P 229004-41-5P 229004-42-6P 229004-43-7P  
229004-44-8P 229004-45-9P 229004-46-0P 229004-47-1P 229004-48-2P  
229004-49-3P 229004-50-6P 229004-51-7P 229004-52-8P 229004-53-9P  
229004-54-0P 229004-55-1P 229004-56-2P 229004-57-3P 229004-58-4P  
229004-59-5P 229004-60-8P 229004-61-9P 229004-62-0P 229004-63-1P  
229004-64-2P 229004-65-3P 229004-66-4P 229004-67-5P 229004-68-6P  
229004-69-7P 229004-70-0P 229004-71-1P 229004-72-2P 229004-73-3P  
229004-74-4P 229004-75-5P 229004-76-6P 229004-77-7P 229004-78-8P  
229004-79-9P 229004-80-2P 229004-81-3P 229004-82-4P 229004-83-5P  
229004-84-6P 229004-85-7P 229004-86-8P 229004-87-9P 229004-88-0P  
229004-89-1P 229004-90-4P 229004-91-5P 229004-92-6P 229004-93-7P  
229004-94-8P 229004-95-9P 229004-96-0P 229004-97-1P 229004-98-2P  
229004-99-3P 229005-00-9P 229005-01-0P 229005-02-1P 229005-03-2P  
229005-04-3P 229005-05-4P 229005-06-5P 229005-07-6P 229005-08-7P  
229005-09-8P 229005-10-1P 229005-11-2P 229005-12-3P 229005-13-4P  
229005-14-5P 229005-15-6P 229005-16-7P 229005-17-8P 229005-18-9P  
229005-19-0P 229005-20-3P 229005-21-4P 229005-22-5P 229005-23-6P  
229005-24-7P 229005-25-8P 229005-26-9P 229005-27-0P 229005-28-1P  
229005-29-2P 229005-30-5P 229005-31-6P 229005-32-7P 229005-33-8P

229005-34-9P	229005-35-0P	229005-36-1P	229005-37-2P	229005-38-3P
229005-39-4P	229005-40-7P	229005-41-8P	229005-42-9P	229005-43-0P
229005-44-1P	229005-45-2P	229005-46-3P	229005-47-4P	229005-48-5P
229005-49-6P	229005-50-9P	229005-51-0P	229005-52-1P	229005-53-2P
229005-54-3P	229005-55-4P	229005-56-5P	229005-57-6P	229005-58-7P
229005-59-8P	229005-60-1P	229005-61-2P	229005-62-3P	229005-63-4P
229005-64-5P	229005-65-6P	229005-66-7P	229005-67-8P	229005-68-9P
229005-69-0P	229005-70-3P	229005-71-4P	229005-72-5P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT	229005-73-6P	229005-74-7P	229005-75-8P	229005-76-9P	229005-77-0P
	229005-78-1P	229005-79-2P	229005-80-5P	229005-81-6P	229005-82-7P
	229005-83-8P	229005-84-9P	229005-85-0P	229005-86-1P	229005-87-2P
	229005-88-3P	229005-89-4P	229005-90-7P	229005-91-8P	229005-92-9P
	229005-93-0P	229005-94-1P	229005-95-2P	229005-96-3P	229005-97-4P
	229005-98-5P	229005-99-6P	229006-00-2P	<b>229006-01-3P</b>	
	<b>229006-02-4P</b>	229006-03-5P	229006-04-6P	229006-05-7P	
	<b>229006-06-8P</b>	229006-07-9P	<b>229006-08-0P</b>	229006-09-1P	
	229006-10-4P	229006-11-5P	<b>229006-12-6P</b>	229006-13-7P	
	229006-14-8P	229006-15-9P	229006-16-0P	229006-17-1P	229006-18-2P
	229006-19-3P	229006-20-6P	229006-21-7P	229006-22-8P	229006-23-9P
	229006-24-0P	229006-25-1P	229006-26-2P	229006-27-3P	229006-28-4P
	229006-29-5P	229006-30-8P	229006-31-9P	229006-32-0P	229006-33-1P
	229006-34-2P	229006-35-3P	229006-36-4P	229006-37-5P	229006-38-6P
	229006-39-7P	229006-40-0P	229006-41-1P	229006-42-2P	229006-43-3P
	229006-44-4P	229006-45-5P	229006-46-6P	229006-47-7P	229006-48-8P
	229006-49-9P	229006-50-2P	229006-51-3P	229006-52-4P	229006-53-5P
	229009-44-3P	229009-45-4P	229009-46-5P	229009-47-6P	229153-64-4P
	229153-65-5P				

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT	75-64-9, tert-Butylamine, reactions	76-05-1, reactions	78-67-1
	96-22-0, 3-Pentanone	96-97-9	98-53-3, 4-tert-Butylcyclohexanone
	99-98-9, 4-Dimethylaminoaniline	100-11-8, 4-Nitrobenzylbromide	
	100-14-1, 4-Nitrobenzylchloride	100-48-1, 4-Cyanopyridine	100-54-9,
	3-Cyanopyridine	100-60-7, N-Cyclohexyl-N-methylamine	100-61-8,
	N-Methylaniline, reactions	100-76-5, Quinuclidine	102-69-2,
	Tripropylamine	103-67-3, N-Methylbenzylamine	103-76-4,
	1-(2-Hydroxyethyl)piperazine	106-41-2, 4-Bromophenol	106-53-6,
	4-Bromothiophenol	107-08-4	107-15-3, 1,2-Ethanediamine, reactions
	108-94-1, Cyclohexanone, reactions	108-99-6, 3-Picoline	109-01-3,
	1-Methylpiperazine	109-04-6, 2-Bromopyridine	109-06-8, 2-Picoline
	110-52-1, 1,4-Dibromobutane	110-68-9, N-Methyl-N-butylamine	110-87-2
	110-89-4, Piperidine, reactions	110-91-8, Morpholine, reactions	
	111-24-0, 1,5-Dibromopentane	111-33-1	111-42-2, reactions
	111-96-6, Bis(2-methoxyethyl)ether	120-92-3, Cyclopentanone	121-44-8,
	reactions	122-00-9	123-75-1, Pyrrolidine, reactions
	Thiomorpholine	288-47-1, Thiazole	358-23-6, Trifluoromethanesulfonic
	acid anhydride	407-14-7, 4-Trifluoromethoxybromobenzene	462-08-8,
	3-Aminopyridine	497-38-1, Norcamphor	502-42-1, Cycloheptanone
	534-03-2, 2-Amino-1,3-propanediol	536-78-7, 3-Ethylpyridine	539-88-8,
	Ethyl levulinate	555-16-8, 4-Nitrobenzaldehyde, reactions	585-70-6,
	5-Bromo-2-furancarboxylic acid	588-96-5, 4-Bromophenetole	591-22-0,
	3,5-Lutidine	591-49-1, 1-Methylcyclohexene	616-44-4
	vanillate	617-05-0, Ethyl	
		617-27-6	619-23-8, 3-Nitrobenzyl chloride
			619-73-8,

4-Nitrobenzylalcohol 620-87-1, 2-(4-Nitrobenzyl)pyridine 625-43-4,  
 N-Methylisobutylamine 626-60-8, 3-Chloropyridine 626-67-5,  
 1-Methylpiperidine 765-58-2, 5-Bromo-2-methylthiophene 766-09-6,  
 1-Ethylpiperidine 766-97-2, 4-Methylphenylacetylene 771-99-3,  
 4-Phenylpiperidine 841-77-0, 1-Benzhydrylpiperazine 930-69-8, Sodium  
 phenylsulfide 998-40-3, Tributylphosphine 1003-09-4, 2-Bromothiophene  
 1072-72-6, 4H-Tetrahydrothiopyran-4-one 1080-32-6, Diethyl  
 benzylphosphonate 1121-92-2 1205-62-5, 4-Nitrobenzylphosphonic acid  
 1450-75-5 1484-84-0, 2-(2-Hydroxyethyl)piperidine 1585-07-5,  
 4-Ethylbromobenzene 1663-39-4 1679-18-1, 4-Chlorophenylboronic acid  
 1692-15-5 1722-12-9, 2-Chloropyrimidine 1761-61-1,  
 5-Bromosalicylaldehyde 1765-93-1, 4-Fluorophenylboronic acid  
 2320-30-1, 3,5-Dimethylcyclohexanone 2338-18-3 2605-67-6 2635-13-4  
 2969-81-5, Ethyl-4-bromobutyrate 3132-99-8, 3-Bromobenzaldehyde  
 3218-02-8, Amino-methylcyclohexane 3287-99-8, Benzylamine hydrochloride  
 3433-37-2, 2-Piperidinemethanol 3490-06-0 3492-64-6 4068-76-2,  
 Methyl-5-bromosalicylate 4606-65-9, 3-(Hydroxymethyl)piperidine  
 4701-17-1, 5-Bromo-2-thiophenecarboxaldehyde 4746-97-8,  
 1,4-Cyclohexanedione monoethyleneketal 5105-78-2 5205-39-0  
 5332-73-0, 3-Methoxypropylamine 5339-26-4, 4-(2-Bromoethyl)nitrobenzene  
 5382-16-1, 4-Hydroxypiperidine 5459-93-8, N-Ethylcyclohexylamine  
 5466-06-8, Ethyl 3-mercaptopropionate 5720-05-8, 4-Methylphenylboronic  
 acid 5794-88-7, 5-Bromoanthranilic acid 6165-69-1 6291-85-6,  
 3-Ethoxypropylamine 6388-74-5, p-Nitrostyreneoxide 6602-32-0,  
 2-Bromo-3-hydroxypyridine 6638-79-5, N,O-Dimethylhydroxylamine  
 hydrochloride 6836-19-7, 7-Methoxy-1-tetralone 6850-65-3,  
 4-Aminocyclohexanol 6859-99-0, 3-Hydroxypiperidine 10544-63-5, Ethyl  
 crotonate 13331-23-2, 2-Furylboronic acid 13331-27-6,  
 3-Nitrophenylboronic acid 13515-93-0, Sarcosine methyl ester  
 hydrochloride 13623-25-1, 6-Methoxy-1-indanone 13952-84-6,  
 1-Methylpropylamine 15300-97-7 16419-60-6 17857-14-6,  
 (3-Carboxypropyl)triphenylphosphonium bromide 18471-73-3,  
 2-(4-Aminophenyl)pyridine 18600-42-5, p-Nitrobenzylamine hydrochloride  
 18664-32-9, 1,3-Dimethoxyacetone 18791-75-8, 4-Bromo-2-  
 thiophenecarboxaldehyde 20074-79-7, Diethyl 4-aminobenzylphosphonate  
 20826-04-4, 5-Bromonicotinic acid 20980-22-7, 1-(2-Pyrimidyl)piperazine  
 23462-75-1, Tetrahydropyran-3-one 24252-37-7, Ethyl 1-methylpiperidine-4-  
 carboxylate 25808-30-4 28611-39-4 29943-42-8, 4H-Tetrahydropyran-4-  
 one 31252-42-3, 4-Benzylpiperidine 32231-06-4, 1-(3,4-  
 Methylenedioxybenzyl)-piperazine 35386-24-4, 1-(2-  
 Methoxyphenyl)piperazine 38212-30-5, 1-(4-Methoxyphenyl)piperazine  
 50541-93-0, 4-Amino-1-benzylpiperidine 50729-68-5 52146-35-7,  
 1-(3,4,5-Trimethoxybenzyl)piperazine 60548-09-6, 1-(2-Furoyl)piperazine  
 hydrochloride 61081-32-1 73579-08-5, 1-Methyl-4-methylaminopiperidine  
 79099-07-3 80670-21-9 82261-42-5, 3-(4-Aminophenyl)pyridine  
 85199-06-0 87779-78-0 89878-14-8, Diethyl-(3-pyridyl)-borane  
 93777-26-5, 5-Bromo-2-fluorobenzaldehyde 96251-92-2 98546-51-1,  
 4-Methylthiophenylboronic acid 128796-39-4, 4-  
 Trifluoromethylphenylboronic acid 162210-31-3 162271-10-5  
 175394-06-6 186498-02-2 229009-38-5 229009-39-6 229009-40-9  
 229009-41-0 229009-42-1 229009-43-2

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides,  
 naphthalenecarboxamides, and related compds. as MCP-1 receptor  
 antagonists)

IT 623-04-1P, 4-Aminobenzyl alcohol 955-44-2P 2089-33-0P 2439-56-7P  
 4519-78-2P, Benzyl-diethylphosphine oxide 5339-15-1P 6149-46-8P  
 6406-74-2P 6425-46-3P 6763-91-3P 6881-57-8P, Benzylphosphonic acid  
 14473-91-7P 15084-55-6P 15115-76-1P 15184-96-0P 16341-77-8P  
 17302-46-4P 18483-99-3P 18484-05-4P 20173-88-0P 20712-12-3P  
 22009-38-7P, 7-Hydroxy-1-tetralone 22237-13-4P, 4-Ethoxyphenylboronic  
 acid 24100-18-3P 29124-57-0P 29608-05-7P 34035-05-7P 34160-40-2P  
 38035-10-8P 40594-34-1P 41526-73-2P, 7-Phenyl-1-tetralone

42870-65-5P 50534-23-1P 50534-24-2P 51013-67-3P 53678-61-8P  
 54306-15-9P 55008-98-5P 55009-03-5P 55580-07-9P 55580-08-0P  
 56851-32-2P 58498-12-7P 59507-44-7P 59507-46-9P 59719-62-9P  
 62157-62-4P 62803-47-8P, 6-Hydroxy-1-indanone 62806-32-0P  
 63139-21-9P, 4-Ethylphenylboronic acid 73676-23-0P 79432-87-4P  
 79909-21-0P 83619-74-3P 91150-58-2P 91953-92-3P 92033-77-7P  
 93138-55-7P 94839-07-3P 95323-86-7P 98008-66-3P 123324-71-0P,  
 4-tert-Butylphenylboronic acid 131230-76-7P 133851-67-9P  
 135605-97-9P 138007-25-7P 139301-27-2P, 4-  
 Trifluoromethoxyphenylboronic acid 142335-64-6P 143632-57-9P  
 144464-65-3P 145654-38-2P 147539-41-1P 160127-63-9P 162607-15-0P  
 162607-20-7P 168897-21-0P 175393-25-6P 175394-17-9P 175840-02-5P  
 179055-22-2P 183608-47-1P 185111-27-7P 229006-54-6P 229006-55-7P  
 229006-56-8P 229006-57-9P 229006-58-0P 229006-59-1P 229006-60-4P  
 229006-61-5P 229006-62-6P 229006-63-7P 229006-64-8P 229006-65-9P  
 229006-66-0P 229006-67-1P 229006-68-2P 229006-69-3P 229006-70-6P  
 229006-71-7P 229006-72-8P 229006-73-9P 229006-74-0P 229006-75-1P  
 229006-76-2P 229006-77-3P 229006-78-4P 229006-79-5P 229006-80-8P  
 229006-81-9P 229006-82-0P 229006-83-1P 229006-84-2P 229006-85-3P  
 229006-86-4P 229006-87-5P 229006-88-6P 229006-89-7P 229006-90-0P  
 229006-91-1P 229006-92-2P 229006-93-3P 229006-94-4P 229006-95-5P  
 229006-96-6P 229006-97-7P 229006-98-8P 229006-99-9P 229007-00-5P  
 229007-01-6P 229007-02-7P 229007-03-8P 229007-04-9P 229007-05-0P  
 229007-06-1P 229007-07-2P 229007-08-3P 229007-09-4P 229007-10-7P  
 229007-11-8P 229007-12-9P 229007-13-0P 229007-14-1P 229007-15-2P  
 229007-16-3P 229007-17-4P 229007-18-5P 229007-19-6P 229007-20-9P  
 229007-21-0P 229007-22-1P 229007-23-2P 229007-24-3P 229007-25-4P  
 229007-26-5P 229007-27-6P 229007-28-7P 229007-29-8P 229007-30-1P  
 229007-31-2P 229007-32-3P 229007-33-4P 229007-34-5P 229007-35-6P  
 229007-36-7P 229007-37-8P 229007-38-9P 229007-39-0P 229007-40-3P  
 229007-41-4P 229007-42-5P 229007-43-6P 229007-44-7P 229007-45-8P  
 229007-46-9P 229007-47-0P 229007-48-1P 229007-49-2P 229007-50-5P  
 229007-51-6P 229007-52-7P 229007-53-8P 229007-54-9P 229007-55-0P  
 229007-56-1P 229007-57-2P 229007-58-3P 229007-59-4P 229007-60-7P  
 229007-61-8P 229007-62-9P 229007-63-0P 229007-64-1P 229007-65-2P  
 229007-66-3P 229007-67-4P 229007-68-5P 229007-69-6P 229007-70-9P  
 229007-71-0P 229007-72-1P 229007-73-2P 229007-74-3P 229007-75-4P  
 229007-76-5P 229007-77-6P 229007-78-7P 229007-79-8P 229007-80-1P  
 229007-81-2P 229007-82-3P 229007-83-4P 229007-84-5P 229007-85-6P  
 229007-86-7P 229007-87-8P 229007-88-9P 229007-89-0P 229007-90-3P  
 229007-91-4P 229007-92-5P 229007-93-6P 229007-94-7P 229007-95-8P  
 229007-96-9P 229007-97-0P 229007-98-1P 229007-99-2P 229008-00-8P  
 229008-01-9P 229008-02-0P 229008-03-1P 229008-04-2P 229008-05-3P  
 229008-06-4P 229008-07-5P 229008-09-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT	229008-11-1P	229008-14-4P	229008-16-6P	229008-18-8P	229008-20-2P
	229008-22-4P	229008-24-6P	229008-26-8P	229008-27-9P	229008-28-0P
	229008-29-1P	229008-30-4P	229008-31-5P	229008-32-6P	229008-33-7P
	229008-34-8P	229008-35-9P	229008-36-0P	229008-37-1P	229008-38-2P
	229008-39-3P	229008-40-6P	229008-41-7P	229008-42-8P	229008-43-9P
	229008-44-0P	229008-45-1P	229008-46-2P	229008-47-3P	229008-48-4P
	229008-49-5P	229008-50-8P	229008-51-9P	229008-52-0P	229008-53-1P
	<b>229008-54-2P</b>	229008-55-3P	<b>229008-56-4P</b>		
	<b>229008-57-5P</b>	229008-58-6P	229008-59-7P	229008-60-0P	
	229008-61-1P	229008-62-2P	229008-63-3P	229008-64-4P	229008-65-5P
	229008-66-6P	229008-67-7P	229008-68-8P	229008-69-9P	229008-70-2P
	229008-71-3P	229008-72-4P	229008-73-5P	229008-74-6P	229008-75-7P
	229008-76-8P	229008-77-9P	229008-78-0P	229008-79-1P	229008-80-4P
	229008-81-5P	229008-82-6P	229008-83-7P	229008-84-8P	229008-85-9P

229008-86-0P 229008-87-1P 229008-88-2P 229008-89-3P 229008-90-6P  
 229008-91-7P 229008-92-8P 229008-93-9P 229008-94-0P 229008-95-1P  
 229008-96-2P 229008-97-3P 229008-98-4P 229008-99-5P 229009-00-1P  
 229009-01-2P 229009-02-3P 229009-03-4P 229009-04-5P 229009-05-6P  
 229009-06-7P 229009-07-8P 229009-08-9P 229009-09-0P 229009-10-3P  
 229009-11-4P 229009-12-5P 229009-13-6P 229009-14-7P 229009-15-8P  
 229009-16-9P 229009-17-0P 229009-18-1P 229009-19-2P 229009-20-5P  
 229009-21-6P 229009-22-7P 229009-23-8P 229009-24-9P 229009-25-0P  
 229009-26-1P 229009-27-2P 229009-28-3P 229009-29-4P 229009-30-7P  
 229009-31-8P 229009-32-9P 229009-33-0P 229009-34-1P 229009-35-2P  
 229009-36-3P 229009-37-4P 229153-66-6P 229153-67-7P 229153-68-8P  
 229153-69-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

IT 229006-01-3P 229006-02-4P 229006-06-8P  
 229006-08-0P 229006-12-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides, naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229006-01-3 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-02-4 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-[(1-oxido-1-phosphorinanyl)methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-06-8 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-N-[4-[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229006-08-0 HCAPLUS

CN 2-Propenamide, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-N-[4-  
[[methyl(tetrahydro-2H-pyran-4-yl)amino]methyl]phenyl]-, (2E)- (9CI) (CA  
INDEX NAME)


Double bond geometry as shown.



RN 229006-12-6 HCAPLUS

CN 2H-Pyran-4-aminium, tetrahydro-N,N-dimethyl-N-[[4-[[[(2E)-3-[5-[4-(1-  
methylethyl)phenyl]-2-thienyl]-1-oxo-2-propenyl]amino]phenyl]methyl]-,  
iodide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

● I<sup>-</sup>

IT 229008-54-2P 229008-56-4P 229008-57-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation of benzoxepinecarboxamides, benzocycloheptenecarboxamides,

naphthalenecarboxamides, and related compds. as MCP-1 receptor antagonists)

RN 229008-54-2 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1-methylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-56-4 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, methyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 229008-57-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-[4-(1,1-dimethylethyl)phenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L48 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1990:552173 HCAPLUS

DN 113:152173

ED Entered STN: 27 Oct 1990

TI Arylation of furanoid compounds with aryldiazonium salts

AU Obushak, N. D.; Ganushchak, N. I.; Lesyuk, A. I.; Dzikovskaya, L. M.; Kisilitsa, P. P.

CS L'vov. Gos. Univ., Lvov, USSR

SO Zhurnal Organicheskoi Khimii (1990), 26(4), 873-80

CODEN: ZORKAE; ISSN: 0514-7492

DT Journal


LA Russian

CC 27-6 (Heterocyclic Compounds (One Hetero Atom))

OS CASREACT 113:152173

GI





- AB Condensation reaction of arylfurfurals I (R = Ph, 4-MeOC<sub>6</sub>H<sub>4</sub>, 4-ClC<sub>6</sub>H<sub>4</sub>, 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 2- and 4-BrC<sub>6</sub>H<sub>4</sub>, 4-tolyl, 1-naphthyl; Z = O) with CH<sub>2</sub>(CO<sub>2</sub>H)<sub>2</sub> in refluxing pyridine containing piperidine gave 58-92% furylacrylic acids I (Z = CHCO<sub>2</sub>H-E), which were arylated with R<sub>1</sub>N<sub>2</sub><sup>+</sup> Cl<sup>-</sup> (R<sub>1</sub> = Ph, 4-ClC<sub>6</sub>H<sub>4</sub>, 2- and 4-BrC<sub>6</sub>H<sub>4</sub>, 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>, 4-EtO<sub>2</sub>CC<sub>6</sub>H<sub>4</sub>) in aqueous Me<sub>2</sub>CO containing NaOAc and CuCl<sub>2</sub> to 8
- I (Z = CHR<sub>1</sub>-E) (II) in 27-54% yield. II were also prepared in 16-40% yield along with 17-32% I (Z = CHO-E) by arylating 3-(2-furyl)acrolein as above. I (R = Ph, 4-ClC<sub>6</sub>H<sub>4</sub>; Z = CHCHO-E) were also formed in 40-50% yield by treating I (Z = O) with MeCHO in H<sub>2</sub>O-CH<sub>2</sub>Cl<sub>2</sub> containing NaOH and BuNEt<sub>3</sub><sup>+</sup> Cl<sup>-</sup>.
- ST arylation furan deriv diazonium salt; styrylfuran furylacrolein prepn UV NMR; furylacrylic acid prepn arylation; acrylic acid furyl prepn arylation; acrolein furyl prepn UV NMR
- IT Nuclear magnetic resonance  
Ultraviolet and visible spectra  
(of (arylfuryl)acroleins and arylstyrylfurans)
- IT Arylation  
(of furanoid compds. with aryldiazonium salts)
- IT Diazonium compounds  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arene, salts, arylation by, of furanoid compds.)
- IT 2028-79-7, 4-(Ethoxycarbonyl)phenyldiazonium chloride 2028-85-5, 4-Bromophenyldiazonium chloride  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation by, of (arylfuryl)acrylic acids)
- IT 100-05-0 100-34-5 2028-74-2, 4-Chlorophenyldiazonium chloride 4346-59-2, 4-Methoxyphenyldiazonium chloride 34835-57-9, 2-Bromophenyldiazonium chloride  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation by, of furylacrolein and (arylfuryl)acrylic acids)
- IT 623-30-3, 3-(2-Furyl)acrolein  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(arylation of, with aryldiazonium chlorides)
- IT 75-07-0, Acetaldehyde, reactions  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(condensation reaction of, with arylfurfurals, (arylfuryl)acroleins by)
- IT 141-82-2, Propanedioic acid, reactions  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(condensation reaction of, with arylfurfurals, (arylfuryl)acrylic acids by)
- IT 7147-77-5, 5-(4-Nitrophenyl)furfural 13803-39-9, 5-Phenylylfurfural 20005-42-9, 5-(4-Bromophenyl)furfural 34035-03-5, 5-(4-Chlorophenyl)furfural 34035-05-7, 5-(4-Tolyl)furfural 34070-33-2, 5-(4-Methoxyphenyl)furfural 51792-36-0 58110-57-9, 5-(2-Bromophenyl)furfural  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(condensation reaction of, with malonic acid, (arylfuryl)acrylic acid by)
- IT 62806-31-9P 62806-32-0P 62806-33-1P 62806-34-2P 62806-35-3P 62806-39-7P **129626-52-4P** 129626-62-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and arylation of, with aryldiazonium salts)
- IT 40025-25-0P 104431-32-5P 108576-24-5P 129626-53-5P 129626-54-6P 129626-55-7P 129626-56-8P 129626-57-9P 129626-58-0P 129626-59-1P

129626-60-4P 129626-61-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


IT 129626-52-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and arylation of, with aryldiazonium salts)

RN 129626-52-4 HCAPLUS

CN 2-Propenoic acid, 3-[5-(2-bromophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX  
NAME)

Double bond geometry as shown.



L48 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1988:510184 HCAPLUS

DN 109:110184

ED Entered STN: 01 Oct 1988

TI Synthesis of substituted furylacrylic acids and their chlorides

AU Lesyuk, A. I.; Dzikovskaya, L. M.; Obushak, N. D.; Ganushchak, N. I.

CS USSR

SO Vestn. L'vov. Un-ta. Ser. Khim. (1987), (28), 82-6

From: Ref. Zh., Khim. 1987, Abstr. No. 22Zh168

DT Journal

LA Russian

CC 27-6 (Heterocyclic Compounds (One Hetero Atom))

OS CASREACT 109:110184

AB Title only translated.

ST arylfurfuryl alc Knoevenagel condensation malonate; furylacrylic acid  
prepn chlorination; furylacryloyl chloride

IT Knoevenagel reaction

(of arylfurfuryl alcs. with malonic acid, furylacrylic acid by)

IT 141-82-2, Malonic acid, reactions

RL: RCT (Reactant); RACT (Reactant or reagent)

(Knoevenagel reaction of, with arylfurfuryl alcs.)

IT 7147-77-5 13803-39-9 20005-42-9 34035-03-5 34035-05-7 34070-33-2  
58110-57-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(Knoevenagel reaction of, with malonic acid)

IT 58110-37-5P 58110-42-2P 58110-43-3P 58110-44-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and conversion of, to acid chloride)

IT 58110-34-2P 58110-40-0P 58110-41-1P 116218-06-5P

116218-07-6P 116218-08-7P 116218-09-8P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


IT 58110-41-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 58110-41-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(2-bromophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)




L48 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1977:188948 HCAPLUS  
 DN 86:188948  
 ED Entered STN: 12 May 1984  
 TI Transmission of substituent effects across the furan ring  
 AU Beno, A.; Krutosikova, A.  
 CS Dep. Anal. Chem., Comenius Univ., Bratislava, Czech.  
 SO Collection of Czechoslovak Chemical Communications (1977), 42(2), 508-11  
 CODEN: CCCCCA; ISSN: 0010-0765  
 DT Journal  
 LA English  
 CC 22-8 (Physical Organic Chemistry)  
 AB The half-wave potential values, apparent dissociation consts., and wavenos. of IR bands of 9 substituted 3-(5-phenyl-2-furyl)acrylic acids and 8 substituted cinnamic acids were correlated with  $\sigma$  substituent consts. The transmission coeffs. across the furan ring,  $\pi'$ , were calculated from the obtained reaction consts.  $\rho$  and compared with the values of  $\pi'$  found for other systems. There was good agreement between the results obtained by different methods., and between the present and previous results (Benó, A., et al., 1973).  
 ST furanacrylic acid Hammett LFER; cinnamic acid Hammett LFER; acid cinnamic furanacrylic Hammett; substituent cinnamic furanacrylic acid; IR cinnamic furanacrylic acid; polarog cinnamic furanacrylic acid  
 IT Dissociation  
 Infrared spectra  
 Polarography  
 (of furyl- and phenylacrylic acids)  
 IT Substituent effect  
 (on properties of cinnamic and furanacrylic acids)  
 IT Linear free energy relationship  
 (Hammett, of furyl- and phenylacrylic acids)  
 IT 940-61-4 940-62-5 7312-27-8 14473-90-6 14737-89-4 17570-26-2  
 20595-30-6 62806-31-9 62806-32-0 62806-33-1 62806-34-2  
 62806-35-3 62806-37-5 62806-38-6  
 RL: PRP (Properties)  
 (dissociation, polarog., and IR of, Hammett relationship of)  
 IT 140-10-3, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (dissociation, polarog., and IR of, Hammett relationship of)  
 IT 62806-36-4 62806-39-7  
 RL: PRP (Properties)  
 (dissociation, polarog., and IR of, Hammett relationship of)  
 IT 62806-36-4  
 RL: PRP (Properties)  
 (dissociation, polarog., and IR of, Hammett relationship of)  
 RN 62806-36-4 HCAPLUS  
 CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




L48 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1976:58390 HCAPLUS  
 DN 84:58390  
 ED Entered STN: 12 May 1984  
 TI Furan derivatives. LXIII. Substituted 3-(5-phenyl-2-furyl)acrylic acids and their methyl esters. Transmission of polar effects across the furan-ethene system  
 AU Krutosikova, A.; Sura, J.; Kovac, J.; Juhas, S.  
 CS Dep. Org. Chem., Slovak Inst. Technol., Bratislava, Czech.  
 SO Collection of Czechoslovak Chemical Communications (1975), 40(11), 3362-9  
 CODEN: CCCCAK; ISSN: 0010-0765  
 DT Journal  
 LA English  
 CC 22-8 (Physical Organic Chemistry)  
 AB Thirteen 3-(5-phenyl-2-furyl)acrylic acids (unsubstituted or substituted by NO<sub>2</sub>, Cl, Br, Me, MeO, or CF<sub>3</sub>) were prepared by Perkin condensation of the corresponding furancarboxaldehydes. The apparent pK<sub>a</sub> values of the acids in 80% methyl cellosolve and the rate consts. kh of the alkaline hydrolysis of their Me esters in 60% aqueous Me<sub>2</sub>CO were determined potentiometrically. The obtained values are correlated with  $\sigma$  substituent consts. and the transmission of the polar effects of the substituents across the furan-ethene system is discussed.  
 ST phenylfuranacrylic acid dissociation const; hydrolysis const  
 phenylfuranacrylate; polar effect phenylfuranacrylate; Hammett  
 phenylfuranacrylate; furanacrylate phenyl polar effect; acrylate  
 phenylfuryl polar effect  
 IT Dissociation  
 (consts., of phenylfuranacrylic acids)  
 IT Kinetics of hydrolysis  
 (of methyl phenylfuranacrylates)  
 IT Substituent effect  
 (on dissociation of phenylfuranacrylic acids or hydrolysis of their methyl esters)  
 IT 7147-77-5 13148-43-1 13803-39-9 20000-96-8 20005-42-9 22078-59-7  
 34035-03-5 34035-04-6 34035-05-7 34070-33-2 52130-30-0  
 58110-57-9 58110-58-0  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (Perkin reaction of)  
 IT 58110-34-2P 58110-35-3P 58110-36-4P 58110-37-5P 58110-38-6P  
 58110-39-7P 58110-40-0P 58110-41-1P 58110-42-2P  
 58110-43-3P 58110-44-4P 58110-45-5P 58110-46-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and dissociation constant of)  
 IT 58110-47-7P 58110-48-8P 58110-49-9P 58110-50-2P 58110-51-3P  
 58110-52-4P 58110-53-5P 58110-54-6P 58110-55-7P 58110-56-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and hydrolysis constant of)  
 IT 58110-38-6P 58110-39-7P 58110-41-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and dissociation constant of)  
 RN 58110-38-6 HCAPLUS  
 CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)




RN 58110-39-7 HCAPLUS

CN 2-Propenoic acid, 3-[5-(2-chlorophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)



RN 58110-41-1 HCAPLUS


CN 2-Propenoic acid, 3-[5-(2-bromophenyl)-2-furanyl]- (9CI) (CA INDEX NAME)



IT 58110-51-3P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and hydrolysis constant of)

RN 58110-51-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-(3-chlorophenyl)-2-furanyl]-, methyl ester (9CI)  
(CA INDEX NAME)

=&gt; =&gt; d all hitstr tot 147

L47 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:455007 HCAPLUS

DN 131:194472

ED Entered STN: 26 Jul 1999

TI Quantitative structure-activity relationship studies of RAR  $\alpha$ ,  
 $\beta$ ,  $\gamma$  retinoid agonists

AU Douguet, Dominique; Thoreau, Etienne; Grassy, Gerard

CS Centre International Recherches Dermatologie GALDERMA, Sophia  
Antipolis, F-06902, Fr.

SO Quantitative Structure-Activity Relationships (1999), 18(2), 107-123

CODEN: QSARDI; ISSN: 0931-8771

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

CC 2-2 (Mammalian Hormones)

- AB Structure-activity relationships were established for 140 synthetic retinoid agonists. Retinoids, natural and synthetic analogs of vitamin A, are activating ligands for retinoic acid receptors (RAR $\alpha$ ,  $\beta$ , and  $\gamma$ ), members of the nuclear receptor superfamily. A QSAR study provides information on the type of intermol. and intramol. interactions the active mols. are exposed to during the course of their interaction with the receptor. Retinoid structures were modeled both by mol. and quantum mechanics and were submitted to a preliminary conformational anal. based on mol. dynamics. Linear and non-linear multivariate analyses were performed, revealing the principal electronic and structural characteristics leading to good affinity for each RAR subtype. Distinct structural features were found for each subtype: this is in agreement with the fact that the selectivity of the RAR subtypes results from the change of amino acids in the ligand cavity. Indeed, these amino-acids induce subtle changes in terms of steric properties and specific interactions, thus engendering specificity. The predictive ability of these relationships was validated using a large set of compds. which were not used to derive the model. The goal this of work was to detect relationships between structures and affinity for a broad range of retinoids in order that this model could be used in a more general manner, for example to impose constraints in database searching, or for use in automatic structure generation software.
- ST retinoid structure activity relationship mol modeling; retinoic acid receptor QSAR
- IT Drug design  
Molecular modeling  
QSAR (structure-activity relationship)  
(QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)
- IT Retinoic acid receptors  
Retinoids  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)
- IT Retinoic acid receptors  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(RAR- $\alpha$ ; QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)
- IT Retinoic acid receptors  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(RAR- $\beta$ ; QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)
- IT Retinoic acid receptors  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(RAR- $\gamma$ ; QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)
- IT 71441-28-6, Ttnpb 86471-16-1 94497-51-5, AM 80 99660-54-5  
99660-64-7 102121-60-8, Am580 104224-10-4 104224-38-6 104224-43-3  
104249-87-8 106685-40-9, Cd 271 106685-58-9 107430-51-3, Cd 0367  
107430-66-0 107430-70-6 107430-75-1 110368-35-9 110952-17-5  
110952-22-2 110952-26-6 111008-33-4 116372-01-1 117168-45-3  
118292-41-4 119435-88-0 119435-89-1 119567-97-4 119568-07-9  
122284-09-7 122284-10-0 122284-13-3 122284-22-4 124434-21-5  
124434-26-0 125316-60-1, CD 437 126070-47-1 131331-96-9  
132392-12-2 132990-98-8 132991-09-4 138254-18-9 139611-80-6  
139611-84-0 139611-93-1 139611-94-2 139642-38-9 142414-06-0  
142650-22-4 142650-36-0 142650-41-7 142651-21-6 143984-56-9  
146670-37-3 146670-40-8 146771-99-5 146965-58-4 146965-61-9  
146965-65-3 146965-69-7 146965-72-2 146965-74-4 146965-76-6

146965-79-9	146966-10-1	153559-46-7	156910-52-0	163161-92-0
170099-86-2	170099-94-2	170355-37-0	170355-67-6	170355-69-8
170355-73-4	170355-74-5	170355-79-0	171365-77-8	171365-79-0
173156-89-3	173156-92-8	173156-93-9	173190-55-1	173191-00-9
173191-01-0	173191-04-3	180528-45-4	183152-91-2	183153-02-8
183153-04-0	183153-06-2	186526-11-4	186526-15-8	186526-17-0
189508-01-8	191469-27-9	192074-09-2	192074-12-7	196929-54-1
196956-73-7	196956-77-1	196956-78-2	196956-80-6	202192-67-4
202192-76-5	202193-09-7	212689-65-1	220543-78-2	241139-99-1
241140-00-1	241140-02-3	241140-04-5	241140-05-6	241140-07-8
241140-08-9	241140-09-0	241140-10-3	241140-11-4	241140-13-6
241140-14-7	241140-15-8	241140-16-9	241140-17-0	241140-18-1
241140-19-2	241140-20-5	241140-21-6	241140-23-8	241140-24-9
241140-25-0	241140-26-1	241140-27-2	241140-28-3	241140-29-4
241140-30-7	241140-31-8	241140-32-9	241140-33-0	
241140-34-1	241140-35-2	241140-36-3		

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)

RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Abraham, R; J Computer Aided Mol Design 1989, V3, P175 HCAPLUS
- (2) Armstrong, R; The Retinoids Biology, Chemistry and Medicine 1994, P545
- (3) Anon; JP 06072866 HCAPLUS
- (4) Bernardon, J; WO 92/06948 1991 HCAPLUS
- (5) Bernardon, J; EP 0661258 A1 1994 HCAPLUS
- (6) Bernardon, J; EP 0661260 A1 1994 HCAPLUS
- (7) Bernardon, J; EP 0679630 A1 1995 HCAPLUS
- (8) Bernardon, J; EP 0679631 A1 1995 HCAPLUS
- (9) Bernardon, J; EP 0722928 A1 1995 HCAPLUS
- (10) Bernardon, J; EP 0776881 A1 1996 HCAPLUS
- (11) Bernardon, J; WO 97/33856 1996 HCAPLUS
- (12) Bernardon, J; WO 97/33881 1997 HCAPLUS
- (13) Bernardon, J; Patent deposited 1998
- (14) Boehm, M; J Med Chem 1994, V37, P2930 HCAPLUS
- (15) Bonchev, D; J Med Chem 1993, V36, P1562 HCAPLUS
- (16) Bonchev, D; J Med Chem 1994, V37, P2300 HCAPLUS
- (17) Boyd, A; Am J Med 1989, V86, P568 MEDLINE
- (18) Carbo, R; Int J Quantum Chem 1980, V17, P1185 HCAPLUS
- (19) Carbo, R; Int J Quantum Chem 1987, V32, P517 HCAPLUS
- (20) Cavey, M; Anal Biochem 1990, V186, P19 HCAPLUS
- (21) Chambon, P; The Faseb J 1996, V10, P940 HCAPLUS
- (22) Chandraratna, R; EP 0284288 1988 HCAPLUS
- (23) Chandraratna, R; EP 0337689 1989 HCAPLUS
- (24) Chandraratna, R; US 5602130 1993 HCAPLUS
- (25) Charpentier, B; WO 92/19583 1992 HCAPLUS
- (26) Charpentier, B; EP 0658553 A1 1994 HCAPLUS
- (27) Charpentier, B; EP 0732328 A1 1996 HCAPLUS
- (28) Charpentier, B; J Med Chem 1995, V38, P4993 HCAPLUS
- (29) Dawson, M; US 5466861 1995 HCAPLUS
- (30) Dawson, M; J Med Chem 1983, V26, P1653 HCAPLUS
- (31) Eustache, J; EP 0210929 1986 HCAPLUS
- (32) Gaillard, P; J Comput-Aided Mol Design 1994, V8, P83 HCAPLUS
- (33) Glass, C; Endocr Rev 1994, V15, P391 HCAPLUS
- (34) Good, A; J Chem Inf Comput Sci 1992, V32, P188 HCAPLUS
- (35) Good, A; J Chem Inf Comput Sci 1993, V33, P112 HCAPLUS
- (36) Grassy, G; Actualites de Chimie Therapeutique 1998, V24 HCAPLUS
- (37) Grassy, G; Eur J Med Chem 1997, V32, P869 HCAPLUS
- (38) Grassy, G; J Mol Graphics 1995, V13, P356 HCAPLUS
- (39) Grassy, G; Nature Biotech 1998, V16, P748 HCAPLUS
- (40) Gudas, L; The Retinoids Biology, Chemistry and Medicine 1994, P443 HCAPLUS
- (41) Hall, L; Rev Comput Chem 1992, V9, P367

- (42) Hong, W; The Retinoids Biology, Chemistry and Medicine 1994, P597 HCAPLUS
- (43) Jaeger, E; Eur J Med Chem 1993, V28, P275 HCAPLUS
- (44) Janssen, B; EP 0386451 1990 HCAPLUS
- (45) Janssen, B; EP 0386452 1990 HCAPLUS
- (46) Kagechika, H; Chem Pharm Bull (Tokyo) 1984, V32, P4209 HCAPLUS
- (47) Kagechika, H; J Med Chem 1989, V32, P834 HCAPLUS
- (48) Karelson, M; Chem Rev 1996, V96, P1027 HCAPLUS
- (49) Klaholz, B; Nature Structural Biology 1998, V5, P199 HCAPLUS
- (50) Loeliger, P; Eur J Med Chem Chim Ther 1980, V15, P9 HCAPLUS
- (51) Maignan, J; EP 0220118 1986 HCAPLUS
- (52) Maignan, J; FR 2601670 1986 HCAPLUS
- (53) Maignan, J; US 5023363 1991 HCAPLUS
- (54) Martin, B; Skin Pharmacol 1992, V5, P57 HCAPLUS
- (55) McFarland, J; J Med Chem 1986, V29, P505 HCAPLUS
- (56) Molecular Simulations Incorporated; InsightII
- (57) Moras, D; Current Opinion in Cell Biology 1998, V10, P384 HCAPLUS
- (58) Oxford Molecular LTD; VAMP
- (59) Oxford Molecular Ltd; ASP, Automated Similarity Package
- (60) Oxford Molecular Ltd; TSAR
- (61) Pawson, B; J Med Chem 1982, V25, P1269 HCAPLUS
- (62) Petkovich, M; Nature 1987, V330, P444 HCAPLUS
- (63) Pfahl, M; WO 98/01132 1996 HCAPLUS
- (64) Renaud, J; Nature 1995, V378, P681 HCAPLUS
- (65) Rocher, J; EP 0514269 A1 1992 HCAPLUS
- (66) Rosen, J; J Med Chem 1995, V38(25), P4855 HCAPLUS
- (67) Shroot, B; FR 2570377 1985 HCAPLUS
- (68) Shroot, B; EP 0199636 1986 HCAPLUS
- (69) Shroot, B; EP 0232199 1987 HCAPLUS
- (70) Shroot, B; FR 2614618 1987 HCAPLUS
- (71) Shroot, B; EP 0325540 1989 HCAPLUS
- (72) Shroot, B; DE 3443230 1996 HCAPLUS
- (73) Shudo, K; EP 0619116 1994 HCAPLUS
- (74) Silla, E; J Comput Chem 1991, V12, P1077 HCAPLUS
- (75) Swann, R; Eur Pat Appl, 0747347A1 1996
- (76) Viswanadhan, V; J Chem Inf Comput Sci 1989, V29, P163 HCAPLUS
- (77) Waterbeemd, H; Pure & Appl Chem 1997, V69(5), P1137

IT 241140-32-9 241140-33-0


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(QSAR studies of retinoic acid receptors  $\alpha$ ,  $\beta$ ,  $\gamma$  retinoid agonists)

RN 241140-32-9 HCAPLUS

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 241140-33-0 HCAPLUS

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, (2E)- (9CI) (CA INDEX NAME)




Double bond geometry as shown.



L47 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2004 ACS on STN  
 AN 1997:623162 HCAPLUS  
 DN 127:293119  
 ED Entered STN: 29 Sep 1997  
 TI Preparation of bicyclic aromatic compounds  
 IN **Bernardon, Jean-Michel**  
 PA Centre International De Recherches Dermatologiques Galderma  
 (C.I.R.D. Galder, Fr.; Bernardon, Jean-Michel  
 SO PCT Int. Appl., 52 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA French  
 IC ICM C07D333-24  
 ICS C07D333-16; C07D307-54; C07D207-32; C07D213-55; C07C069-618;  
 A61K031-38; A61K031-19  
 CC 27-1 (Heterocyclic Compounds (One Hetero Atom))  
 Section cross-reference(s): 1, 25, 62, 63  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9733881	A1	19970918	WO 1997-FR391	19970305 <--
W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
FR 2746101	A1	19970919	FR 1996-3235	19960314 <--
FR 2746101	B1	19980430		
CA 2218766	AA	19970918	CA 1997-2218766	19970305 <--
CA 2218766	C	20030715		
AU 9720305	A1	19971001	AU 1997-20305	19970305 <--
AU 704753	B2	19990506		
EP 832081	A1	19980401	EP 1997-908308	19970305 <--
EP 832081	B1	20030129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
CN 1190394	A	19980812	CN 1997-190489	19970305 <--
CN 1109031	B	20030521		
JP 10509987	T2	19980929	JP 1997-532318	19970305 <--
JP 2991502	B2	19991220		
BR 9702200	A	19990720	BR 1997-2200	19970305 <--
AT 231852	E	20030215	AT 1997-908308	19970305 <--
PT 832081	T	20030630	PT 1997-97908308	19970305 <--
ES 2192668	T3	20031016	ES 1997-908308	19970305 <--
NO 9705192	A	19980114	NO 1997-5192	19971112 <--
US 6147255	A	20001114	US 1998-952804	19980126 <--

US 6515021	B1	20030204	US 2000-619582	20000912 <--
US 2003060491	A1	20030327	US 2002-252514	20020924 <--
CN 1443756	A	20030924	CN 2002-152959	20021129 <--
US 2003135053	A1	20030717	US 2003-334978	20030102 <--
PRAI FR 1996-3235	A	19960314 <--		
WO 1997-FR391	W	19970305 <--		
US 1998-952804	A1	19980126		
US 2000-619584	A1	20000719		
US 2000-619582	A3	20000912		
OS MARPAT 127:293119				
GI				



AB Novel bicyclic aromatic compds. I [R1 = Me, CH2OR5, COR6; Ar = (un)substituted Ph, pyridyl, furyl, thienyl, pyrrolyl; X = CR8:CR9, C.tplbond.C; R2, R3 = H, alkyl, OR5, SR5; R2R3 = aromatic ring; R5 = H, alkyl, acyl; R6 = H, alkyl, NR'R''; R8, R9 = H, alkyl] and their use in pharmaceutical compns. useful in treatment of dermatol. conditions (no data) or their use in cosmetic compns. (no data) are disclosed. E.g., reaction of 3-tert-butyl-4-methoxyphenylboronic acid and 4-bromo-2-thiophenecarboxaldehyde gave 4-(3-tert-butyl-4-methoxyphenyl)-2-thiophenecarboxaldehyde. The last was treated with tri-Et phosphonoacetate to give Et 4-(3-tert-butyl-4-methoxyphenyl)-2-thiopheneacrylate. The ester was converted to the corresponding acid.

ST bicyclic arom compd prepn; naphthylthiopheneacrylic acid prepn; thiopheneacrylic acid naphthyl prepn; naphthylphenylpropionic acid prepn; propionic acid naphthylphenyl prepn; pyrrolylacrylic acid naphthyl prepn; dermatol agent bicyclic arom compd; cosmetic agent bicyclic arom compd

IT Aromatic compounds  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of bicyclic aromatic compds.)

IT Cosmetics  
 (preparation of bicyclic aromatic compds. as cosmetic agents)

IT Skin preparations (pharmaceutical)  
 (preparation of bicyclic aromatic compds. as dermatol. agents)

IT 196960-59-5P 196960-60-8P 196960-61-9P  
 196960-62-0P 196960-63-1P 196960-64-2P  
 196960-65-3P 196960-66-4P 196960-67-5P 196960-68-6P  
 196960-69-7P 196960-70-0P 196960-71-1P 196960-72-2P 196960-73-3P  
 196960-74-4P 196960-75-5P 196960-76-6P 196960-77-7P 196960-78-8P  
 196960-79-9P 196960-80-2P 196960-81-3P 196960-82-4P 196960-83-5P  
 196960-84-6P 196960-85-7P 196960-86-8P 196960-87-9P 196960-88-0P  
 196960-89-1P 196961-42-9P 196961-43-0P 196961-44-1P 196961-45-2P  
 196961-47-4P 196961-49-6P 196961-50-9P 196961-51-0P 196961-52-1P  
 196961-53-2P 196961-54-3P 196961-55-4P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of bicyclic aromatic compds.)

IT 99-90-1 108-40-7, 3-Methylthiophenol 110-91-8, Morpholine, reactions

123-30-8, 4-Hydroxyaniline 629-04-9, 1-Bromoheptane 870-63-3  
 931-33-9 1122-91-4, 4-Bromobenzaldehyde 1200-07-3 1761-61-1,  
 5-Bromo-2-hydroxybenzaldehyde 4701-17-1 14804-34-3 18791-75-8  
 27452-17-1 62224-19-5 119999-22-3 168082-64-2 170355-38-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of bicyclic aromatic compds.)

IT 33694-79-0P 135631-86-6P 158115-92-5P 168082-41-5P 169126-63-0P  
 169126-64-1P 170100-73-9P 189698-90-6P 189698-91-7P 189699-37-4P  
 191469-48-4P 196960-90-4P 196960-91-5P 196960-92-6P 196960-93-7P  
 196960-94-8P 196960-95-9P 196960-96-0P 196960-97-1P 196960-98-2P  
 196960-99-3P **196961-00-9P** 196961-01-0P **196961-02-1P**  
 196961-03-2P **196961-04-3P** 196961-05-4P **196961-06-5P**  
 196961-07-6P **196961-08-7P** 196961-09-8P 196961-10-1P  
 196961-11-2P 196961-12-3P 196961-13-4P 196961-14-5P 196961-15-6P  
 196961-16-7P 196961-17-8P 196961-18-9P 196961-19-0P 196961-20-3P  
 196961-21-4P 196961-22-5P 196961-23-6P 196961-24-7P 196961-25-8P  
 196961-26-9P 196961-27-0P 196961-28-1P 196961-29-2P 196961-30-5P  
 196961-31-6P 196961-32-7P 196961-33-8P 196961-34-9P 196961-35-0P  
 196961-36-1P 196961-37-2P 196961-38-3P 196961-39-4P 196961-40-7P  
 196961-41-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bicyclic aromatic compds.)


IT **196960-59-5P 196960-61-9P 196960-62-0P**  
**196960-63-1P 196960-64-2P 196960-65-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of bicyclic aromatic compds.)


RN 196960-59-5 HCAPLUS

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-(9CI) (CA INDEX NAME)




RN 196960-61-9 HCAPLUS

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-(9CI) (CA INDEX NAME)




RN 196960-62-0 HCAPLUS

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-(9CI) (CA INDEX NAME)




RN 196960-63-1 HCAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




RN 196960-64-2 HCAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)



RN 196960-65-3 HCAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]- (9CI) (CA INDEX NAME)




IT 196961-00-9P 196961-02-1P 196961-04-3P

196961-06-5P 196961-08-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of bicyclic aromatic compds.)


RN 196961-00-9 HCAPLUS

CN 2-Propenoic acid, 3-[5-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-3-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-02-1 HCAPLUS

CN 2-Propenoic acid, 3-[4-[3-(1,1-dimethylethyl)-4-methoxyphenyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-04-3 HCAPLUS

CN 2-Propenoic acid, 3-[5-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 196961-06-5 HCAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 196961-08-7 HCAPLUS

CN 2-Propenoic acid, 3-[4-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



=>